[COMPANY_001] Research and Development  
AIN457 
Clinical Trial Protocol CAIN457S12201 / [STUDY_ID_REMOVED]
A
 proof of concept study t o evaluate the e fficacy, s afety 
and tolerabilit y of secukinumab 300 mg over 32 weeks in 
adult patients with biopsy -proven forms of lichen planus 
not adequately c ontrolle d with topi[INVESTIGATOR_12491] - PRELUDE 
Document type:  Clinical Trial Protocol Amendment  
EUDRACT number:  2019 -003588 -24 
Version number:  02 (Clean ) 
Clinical Trial Phase:  II 
Release date:  26-Oct-2020
Property of [COMPANY_001]  
Confidential  
May not be used, divulged, published, or otherwise disclosed  
without the consent of [COMPANY_001]  
Clinical Trial Protocol Template Version 2.0 dated 01- Aug- 2018  
[COMPANY_001]  Confidential  Page 2 
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
Table of contents 
Table of contents ................................................................................................................. [ADDRESS_410553] of abbreviations ............................................................................................................ 7 
Glossary of terms  ............................................................................................................... 10 
Amendment 02 ......................................................................................................................... 12 
Amendment 01 ......................................................................................................................... 13 
Protocol summary .............................................................................................................. 15 
1 Introduction ....................................................................................................................... 18 
1.1 Background ............................................................................................................ 18 
1.2 Purpose .................................................................................................................. 19 
2 Objectives and endpoints ................................................................................................... 20 
3 Study design ...................................................................................................................... 22 
4 Rationale  ............................................................................................................................ 25 
4.1 Rationale for study design ..................................................................................... 25 
4.2 Rationale for choice of background therapy .......................................................... 27 
4.3 Rationale for dose/regimen and duration of treatment .......................................... 27 
4.4 Rationale for choice of control drugs .................................................................... 29 
4.5 Purpose and timing of interim analyses/design adaptations .................................. 30 
4.6 Risks and benefits .................................................................................................. 30 
5 Population .......................................................................................................................... 32 
5.1 Inclusion criteria  .................................................................................................... 32 
5.2 Exclusion criteria  ................................................................................................... 32 
6 Treatment  ........................................................................................................................... 35 
6.1 Study treatment ...................................................................................................... 35 
6.1.1 Investigational and control drugs .......................................................... 35 
6.1.2 Additional study treatments  .................................................................. 35 
6.1.3 Treatment arms/group  ........................................................................... 35 
6.1.4 Treatment duration  ................................................................................ 36 
6.2 Other treatment(s)  .................................................................................................. [ADDRESS_410554] numbering ................................................................................ 40 
6.3.2 Treatment assignment, randomization  .................................................. 40 
[COMPANY_001]  Confidential  Page 3 
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
6.[ADDRESS_410555] demographics/other baseline characteristics  ............................................. 54 
8.2.1 Demography .......................................................................................... 54 
8.2.2 Prior Lichen Planus medical history and previous therapi[INVESTIGATOR_014] ................ 54 
8.2.3 Smoking history .................................................................................... 55 
8.2.4 Medical history/current medical conditions .......................................... 55 
8.2.5 Prior and concomitant medications ....................................................... 55 
8.2.6 Determination of the tuberculosis status  ............................................... 55 
8.3 Efficacy  .................................................................................................................. 55 
8.3.1 Investigator’s Global Assessment (IGA)  .............................................. 55 
8.3.2 Physician´s assessment of surface area of disease (PSAD)  .................. 57 
8.3.3 Reticulations, e rythema and ulcerations (REU) score .......................... 58 
8.3.4 Lichen planopi[INVESTIGATOR_178370] (LPPAI) ......................................... 59 
8.3.5 Appropriateness of efficacy assessments  .............................................. 59 
8.4 Safety/Tolerability  ................................................................................................. 60 
8.4.1 Laboratory evaluations  .......................................................................... 62 
8.4.2 Pregnancy  .............................................................................................. 63 
8.4.3 Appropriateness of safety measurements  .............................................. 63 
8.5 Additional assessments  .......................................................................................... 63 
8.5.1 Patient Reported Outcomes (PROs)  ...................................................... 64 
  66 
  67 
  67 
8.5.5 Other Assessments  ................................................................................ 69 

[COMPANY_001]  Confidential  Page 4 
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
[ADDRESS_410556]-study treatment .......................................................... 71 
10 Safety monitoring and reporting ........................................................................................ 72 
10.1 Definition of adverse events and reporting requirements ...................................... 72 
10.1.1 Adverse event s ...................................................................................... 72 
10.1.2 Serious adverse events  .......................................................................... 74 
10.1.3 SAE reporting........................................................................................ 75 
10.1.4 Pregnancy reporting .............................................................................. 75 
10.1.5 Reporting of study treatment errors including misuse/abuse ................ [ADDRESS_410557] demographics and other baseline characteristics  ...................................... 79 
12.3 Treatments  ............................................................................................................. 79 
12.4 Analysis of the primary endpoint(s) ...................................................................... 79 
12.4.1 Definition of primary endpoint(s) ......................................................... 79 
12.4.2 Statistical model, hypothesis, and method of analysis .......................... 79 
12.4.3 Handling of missing values/censoring/discontinuations ....................... 80 
12.4.4 Sensitivity and Supportive analyses ...................................................... 80 
12.5 Analysis of secondary endpoints ........................................................................... 80 
12.5.1 Efficacy and/or Pharmacodynamic endpoint(s) .................................... 80 
12.5.2 Safety endpoints .................................................................................... 82 
  83 
  83 
  83 
12.5.6 PD relationships  .............................................................................. 83 

[COMPANY_001]  Confidential  Page 5 
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
12.5.7 Patient reported outcomes ..................................................................... 83 
  83 
12.7 Interim analyses  ..................................................................................................... 84 
12.8 Sample size calculation  .......................................................................................... 84 
13 Ethical considerations and administrative procedures ...................................................... 86 
13.1 Regulatory and ethical compliance ........................................................................ 86 
13.2 Responsibilities of the investigator and IRB/IEC .................................................. 86 
13.3 Publication of study protocol and results............................................................... 86 
13.4 Quality Control and Quality Assurance ................................................................. 86 
13.5 Protocol adherence  ................................................................................................. 87 
13.6 Protocol amendments  ............................................................................................. 87 
14 References  ......................................................................................................................... 88 
15 Appendices ........................................................................................................................ 91 
15.1 Appendix 1: Clinically notable laboratory values and vital signs ......................... 91 
 
 92 
15.3 Appendix 2: Determination of Tuberculosis status ............................................... [ADDRESS_410558] of tables 
Table 2 -1 Objectives and related endpoints .......................................................... 20 
Table 6 -1 Investigational and control drug ............................................................ 35 
Table 6 -2 Prohibited medication  ........................................................................... 38 
Table 8 -1 Assessment Schedule  ............................................................................ 47 
Table 8 -2 Investigator's Global Assessment grading ............................................ 56 
Table 8 -3 LPPAI  .................................................................................................... 59 
Table 8 -4 Assessments &  Specifications  ............................................................... 61 
Table 10 -1 Guidance for capturing the study treatment errors including 
misuse/abuse ......................................................................................... [ADDRESS_410559] of figures 
Figure 3-1 Study design .......................................................................................... 25 
Figure 4-1 Predicted systemic exposure of the every 2 and every 4 weeks 
dosing intervals during maintenance at the 300 mg dose level ............. 29 

[COMPANY_001]  Confidential  Page 6 
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
Figure 12-1 Operating Characteristics on different randomization ratio and 
different response rate assumption  ........................................................ 85 
Figure 15-1 Tuberculosis screening flowchart ......................................................... 95 
 
[COMPANY_001]  Confidential  Page 7 
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
List of abbreviations 
AE Adverse event  
ALT alanine aminotransferase  
AST aspartate aminotransferase  
β-hCG  beta-human chorionic gonadotropin  
BDR  Bioanalytical Data Report  
BSA Body Surface Area  
BSL Baseline  
CFR Code of Federal Regulation  
ClinRO  Clinician reported outcome  
CLP Cutaneous lichen planus  
  
CMO & 
PS Chief Medical Office and Patient Safety  
CO Country organization  
CRA  Clinical Research Associate  
CRF Case report form  
CRO  Contract Research Organization  
CSR  Clinical study report  
CTRD  Clinical Trial Results Database  
CTT Clinical Trial Team  
  
CVID  Common variable immunodeficiency  
DDE  Direct data entry  
DLQI  Dermatology Life Quality Index   
  
EDC  Electronic Data Capture  
  
EMA  European Medicines Agency  
EOT End of treatment  
eSAE  electronic Serious Adverse Event  
  
EU European Union  
FAS Full Analysis  Set 
FDA Food and Drug Administration  
FFA Frontal fibrosing alopecia  
GCP  Good Clinical Practice  
GCS  Global Clinical Supply  
GGT  Gamma -Glutamyl -Transferase   
h hour 
H  Home administrations  
HbA1c  Hemoglobin A1c  

[COMPANY_001]  Confidential  Page 8 
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
HBsAg  Hepatitis B surface antigen  
HDL High density lipoprotein  
HIV human immunodeficiency virus  
HRQoL  Health -related quality of life  
hs-CRP  High sensitivity C -reactive protein  
IB Investigator Brochure  
ICF Informed consent form  
ICH International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use  
IEC Independent Ethics Committee  
IFU Instructions for use  
  
IGA Investigator’s Global Assessment   
IL-17A Interleukin 17A  
IN Investigator Notification  
IRB Institutional Review Board  
IRT Interactive Response Technology  
IUD Intrauterine device  
IUS Intrauterine system  
LDH Lactate dehydrogenase  
LDL Low density lipoprotein  
LLN lower limit of normal  
LLOQ  Lower limit of quantification  
LP Lichen planus  
LPP Lichen planopi[INVESTIGATOR_331923](s)  
mL milliliter(s)  
MLP Mucosal lichen planus  
NCDS  [COMPANY_001] Clinical Data Standards  
NCT National clinical trial  
NRS  Numerical rating scale  
OLP Oral lichen planus  
OLPSSM  Oral Lichen Planus Symptom Severity Measure   
OTC  Over the counter  
PBO  Placebo  
PD Pharmacodynamic(s)  
PFS Pre-filled syringe  
   
   
  

[COMPANY_001]  Confidential  Page 9 
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
PoC Proof -of-concept  
[COMPANY_003] Purified protein derivative  
PRO  Patient reported outcome  
PSAD  Physician´s assessment of surface area of disease  
PUVA  Psoralen and Ultraviolet A  
Q2W  Once every 2 weeks  
Q4W  Once every 4 weeks  
QFT QuantiFERON® TB-Gold test  
QMS  Quality Management System  
RAS Randomized Analysis Set  
RDC  Remote Data Capture  
REU  Reticulations, erythema and ulcerations  
RoW  Rest of the World  
RPM  Revolutions Per Minutes  
s.c. subcutaneous  
SAE serious adverse event  
SC Steering Committee  
sCR serum creatinine  
SD standard deviation  
SGOT  serum glutamic oxaloacetic transaminase  
SGPT  serum glutamic pyruvic transaminase  
SOP  Standard Operating Procedures  
SST Serum Separator Tubes  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reactions  
TB Tuberculosis  
TBL total bilirubin  
TNF Tumor necrosis factor  
ULN upper limit of normal  
ULQ upper limit of quantification  
US [LOCATION_002] of America  
UVA Ultraviolet A  
UVB Ultraviolet B  
WHO  World Health Organization  
Wk Week  
WoC  Withdrawal of Consent  
[COMPANY_001]  Confidential  Page 10  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
Glossary of terms 
Assessment  A procedure used to generate data required by [CONTACT_90166]  A specific group of subjects fulfilling certain criteria  
Control drug  A study drug used as a comparator to reduce assessment bias, preserve 
blinding of investigational drug, assess internal study validity, and/or evaluate 
comparative effects of the investigational drug.  
Dosage  Dose of the study treatment given to the subject in a time unit (e.g. 100 mg 
once a day, 75 mg twice a day)  
Enrollment  Point/time of subject entry into the study at which informed consent must be 
obtained (i.e. prior to starting any of the procedures described in the protocol)  
Epoch  Interval of time in the planned conduct of a study. An epoch is associated with a purpose (e.g. screening, randomization, treatment, follow -up), which applies 
across all arms of a study.  
Estimand  A structured framework that translate the trial objective into a precise definition 
of the tr eatment effect that is to be estimated  
Healthy volunteer  A person with no known significant health problems who volunteers to be a 
study participant  
Investigational 
drug The study drug whose properties are being tested in the study; this definition is consistent with US CFR 21 Section 312.3 and is synonymous with 
“investigational new drug” or “investigational medicinal product”.  
Investigational 
treatment  All investigational drug(s) whose properties are being tested in the study as well as  their associated treatment controls. This includes any placebos, any 
active controls, as well as approved drugs used outside of their indication/approved dosage or tested in a fixed combination. Investigational treatment generally does not include other t reatments administered as 
concomitant background therapy required or allowed by [CONTACT_331985]/dosage.  
Medication 
number  A unique identifier on the label of each study drug package in studies that 
dispense study drug usi ng an IRT system.  
Medication pack 
number  A unique identifier on the label of each drug package in studies that dispense 
study treatment using an IRT system  
Part A single component of a study that contains different objectives or populations 
within that single study. Common parts within a study are: a single dose part 
and a multiple dose part, or a part in patients with established disease and in 
those with newly -diagnosed disease.  
Patient  An individual with the condition of interest  
Period  A minor subdivision of the study timeline; divides phases into smaller functional 
segments such as screening, baseline, titration, washout, etc.  
Premature subject 
withdrawal  Point/time when the subject exits from the study prior to the planned completion of all s tudy drug administration and assessments; at this time all study drug 
administration is discontinued and no further assessments are planned.  
Randomization 
number  A unique identifier assigned to each randomized subject, corresponding to a 
specific treatmen t arm assignment  
Screen Failure  A subject who is screened but is not treated or randomized  
Stage  A major subdivision of the study timeline; begins and ends with major study 
milestones such as enrollment, randomization, completion of treatment, etc.  
Study completion  Point/time at which the subject came in for a final evaluation visit or when study 
drug was discontinued whichever is later.  
[COMPANY_001]  Confidential  Page 11  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
Study drug 
discontinuation  Point/time when subject permanently stops taking study drug for any reason; 
may or may not  also be the point/time of premature subject withdrawal.  
Study treatment  Any drug administered to the study participants as part of the required study 
procedures; includes investigational drug (s), control(s) or non- investigational 
medicinal product(s)  
Study treatment 
discontinuation  When the subject permanently stops taking study treatment prior to the defined 
study treatment completion date  
Subject  An individual who has consented to participate in this study. The term Subject 
may be used t o describe either a healthy volunteer or a patient.  
Subject number  A unique number assigned to each subject upon signing the informed consent. 
This number is the definitive, unique identifier for the subject and should be 
used to identify the subject throughout the study for all data collected, sample 
labels, etc.  
Treatment 
number  A unique identifier assigned in non- randomized studies to each dosed subject, 
corresponding to a specific treatment arm  
Variable  Information used in the data analysis; derived  directly or indirectly from data 
collected using specified assessments at specified timepoints.  
Withdrawal of 
consent (WoC)  Withdrawal of consent from the study is defined as when a subject does not w
ant to participate in the study any longer, and does not want any further visits 
or assessments, and does not want any further study related contact, and does 
not allow analysis of already obtained biologic material  
[COMPANY_001]  Confidential  Page 12  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
Amendment [ADDRESS_410560] been updated or corrected as well to further optimize the clinical trial 
protocol. 
Changes to the protocol  
Changes to specific sections of  the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined font for insertions. 
Changes to the protocol include: 
• Section 8.5.[ADDRESS_410561] the treatment of study subjects.  
IRBs/IECs  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol are non- substantial and do not require IRB/IEC 
approval prior to implementation.  
The changes herein do NOT affect the trial specific model ICF.  
  
[COMPANY_001]  Confidential  Page 13  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
Summary of previous amendments  
Amendment 01 
Amendment rationale   
There are three major reasons for t his amendment:  
The first one is an update of the IGA score specifications. Certain criteria of the score have been 
changed in a way that the score in its amended version is more specific regarding certain aspects of the disease, its clinical application h as become easier and it now covers cases which were 
not covered before.   
The second major reason is to allow the use of historical biopsies (if available) at screening for 
patients of all three subtypes of lichen planus instead of allowing it for the lichen planopi[INVESTIGATOR_331924]. This makes the trial more patient friendly and reduces the need for biopsies. 
The third major reason is to adapt the protocol to pandemic/ epi[INVESTIGATOR_331925]. In case of a pandemic/ 
epi[INVESTIGATOR_901], sites are given the opportunity for home shipment of study drug and urine pregnancy tests, as well as phone calls for safety assessment. The purpose of this is to protect patients as well as site staff by r educing personal exposure and thereby [CONTACT_331986] (e.g. COVID-19) while maintaining adequate safety monitoring. 
Other, minor points have been updated or corrected as well to further optimize the clinical trial 
protocol. 
Changes to the protocol  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions. 
Changes to the protocol include: 
• Table 2 -1 has been modified to enlarge Patient assessment of itch to all LP sub -types 
• Section [ADDRESS_410562] been clarified  
• Section 5.2, Inflammatory Bowel Disease has been added as an example to Exclusion 
criter ion #15 
• Section 6.1.3 has been corrected to enlarge the use of historical biopsy for inclusion to 
all LP subtypes 
• Section 6.2.1, Section 6.2.2, List of allow ed and forbidden medications has been 
corrected and clarified  
• Section 6.[ADDRESS_410563] safety information 
in case of pandemic / epi[INVESTIGATOR_331926] 14  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
• Section [ADDRESS_410564] safety information in case of pandemic / epi[INVESTIGATOR_13000]  
• Section [ADDRESS_410565] been clarified ,  
• Section 8.1, criteria for re -screening have been clarified  
• Table [ADDRESS_410566] been further defined, and flow of visits clarified; timing of urine pregnancy tests has also been corrected  
• Table 8 -2, the Investigator’s Global Assessment grading has been modified 
• Section 8.3.2, Assessment scoring for Physician’s assessment of surface area of disease 
has been corrected  
• Section 8.4.2, Section 8.5.4 Timing of urine pregnancy tests has been corrected 
• Section 8.5.4 has been corrected to enlarge the use of historical biopsy for inclusion to 
all LP subtypes 
• Section 9.1.1, Section 9.1.2, Section 9.2, End of treatment and End of study have been 
further defined and flow of visits clarified  
• Section 10.1.4, Need for requiring a signed pregnancy ICF to follow up on any 
pregnancy has been added 
Editorial revisions, clarific ations and corrections have also been made throughout the protocol . 
[COMPANY_001]  Confidential  Page 15  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
Protocol summary  
 
Protocol number  CAIN457S12201  
Full Title  A proof -of-concept study to evaluate the efficacy, safety and tolerability of 
secukinumab 300 mg over 32 weeks in adult patients with biopsy -proven 
forms of lichen planus not adequately controlled with topi[INVESTIGATOR_12491] - 
PRELUDE  
Brief title  Study of efficacy and safety of secukinumab 300 mg in adult patients with 
biopsy -proven forms of lichen planus  
Sponsor and 
Clinical Phase  [COMPANY_001]/Phase II  
Investigation type  Drug  
Study type  Interventional  
Purpose and 
rationale  Lichen planus (LP) is an inflammatory disease affecting different locations of the body (skin, oral cavity, genitalia, scalp, and nails).  
Current therapi[INVESTIGATOR_331927]. However, 30- 50% of patients are 
refractory to available therapi[INVESTIGATOR_331928], as well as significant psychological discomfort and 
social disability resulting in profoundly impaired quality of life.   
This is a multicenter, randomized, double- blind, placebo- controlled, parallel-
group trial assessing the efficacy and safety of secukinumab 300 mg in two different dosing regimens in patients with biopsy -
proven forms of lichen 
planus, for which no systemic therapy is currently approved and which could 
be eligible for treatment w ith secukinumab.  
Primary Objective(s)  The primary objective of this study is to evaluate the efficacy secukinumab when compared to placebo after 16 weeks of treatment, by [CONTACT_331987]'s Global Assessment (IGA) 
response where IGA response is defined as achievement  of absolute IGA 
score less or equal 2  (IGA ≤2).  
Secondary 
Objectives  Objective 1: t o evaluate the efficacy of secukinumab 300 mg Q4W compared 
to placebo throughout  16 weeks  in Treatment Period 1 and to evaluate the 
long term efficacy of secukinumab 300 mg Q4W throughout  32 weeks in 
Treatment Period 2 and evaluate the efficacy  of secukinumab 300 mg Q2W 
in Treatment Period 2 by [CONTACT_10670]'s Global Assessment (IGA ), 
Dermatology Life Quality Index (DLQI), Physician Assessment of Surface Area of Disease (PSAD) for Skin Disease, Patient assessment of itch (Numerical Rating Scale - NRS), Reticular Erythematous Ulcerative (REU) 
score, Oral Lichen Planus Symptoms Severity Measure (OLPSSM) score, 
Patient assessment of pain (NRS), LPP Activity Index (LPPAI), SCALPDEX 
Questionnaire.  
Objective 2: t o assess the safety and tolerability of secukinumab in subjects 
with lichen planus by [CONTACT_20721]  (AEs) , laboratory values, vit al signs from 
baseline to end of study visit.  
Study design  This is a multicenter, randomized, double- blind, placebo -controlled, parallel -
group study in approximately 108 patients with biopsy -proven lichen planus.  
The study consists of: Screening (up to 4 weeks), Treatment Period 1 (16 
weeks), Treatment Period 2 (16 weeks). Subjects who prematurely 
[COMPANY_001]  Confidential  Page 16  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
discontinue the study, or who complete the study, will enter a post -treatment 
Follow -Up period (8 weeks).  
Population  The study population will consist of adul t subjects (≥ 18 years) with biopsy -
proven lichen planus. It is planned to randomize approximately 108 subjects 
in approximately 36 study sites worldwide. At randomization, the subjects will 
be assigned to one of the 3 cohorts (predominant cutaneous lichen planus  
(CLP) , predominant mucosal lichen planus (MLP) and lichen planopi[INVESTIGATOR_22785]  
(LPP) ) according to the clinical features present.  
Key Inclusion criteria  1. Written informed consent must be obtained before any assessment is performed.  
2. Female and male patients ≥ [ADDRESS_410567] biopsy -confirmed forms of cutaneous lichen planus 
(CLP), mucosal lichen planus (MLP), or active lichen planopi[INVESTIGATOR_22785] (LPP) eligible for systemic therapy based on the following criteria:  
· Rated IGA of ≥ 3 (moderate or severe) at screening and baseline AND  
· Inadequate response to topi[INVESTIGATOR_331929] - ultrahigh potency in 
the opi[INVESTIGATOR_331930]  1. Clinical history suspi[INVESTIGATOR_331931].  
2. Lichen planus pi[INVESTIGATOR_331932].  
3. Clinical pi[INVESTIGATOR_331933].  
4. Subjects whose lichen planus is a predominantly bullous variant.  
5. Mucosal lichen planus of the oral cavity or gastrointestinal i nvolvement 
requiring the patient to use parenteral nutrition or feeding tube.  
6. Clinical pi[INVESTIGATOR_331934] -out cicatricial alopecia (alopecia of Brocque)  
7. Patients diagnosed with frontal fibrosing alopecia (FFA) without active 
patches of LPP.  
8. Previous exposure to any other biologic drug directly targeting IL- 17A or IL-
17RA (e.g. ixekizumab or brodalumab) or IL- 23/p19 (e.g. tildrakizumab, 
guselkumab, risankizumab).  
9. Hepatitis C antibody positive at screening unless viral load is 0.  
Study treatment 1. Secukinumab 300 mg, provided as 2 s.c. injections of 1 ml prefilled 
syringe (PFS). Each 1 ml syringe contains 150 mg secukinumab.  
2. Placebo, provided as 2 s.c. injections of 1 ml prefilled syringe (PFS).  
Efficacy 
assessments  Efficacy assessments related to the primary and secondary objectives include:  
Clinician Reported Outcomes (ClinRO) assessed by [CONTACT_093]  
• Investigator ’s Global Assessment (IGA)  
• Physician Assessment of Surface Area of Disease (PSAD)  
• Reticulation, Erythema and Ulcerations score (REU)  
• Lichen Planopi[INVESTIGATOR_178370] (LPPAI)  
Patient reported outcomes (PRO) assessed by [CONTACT_423]:  
  
  

[COMPANY_001]  Confidential  Page 17  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
• Patient assessment of itch (NRS)  
• Patient assessment of pain  (NRS)  
• Oral Lichen Planus Symptom Severity Measure (OLPSSM)  
• Dermatology Life Quality Index (DLQI)  
  
• SCALPDEX  
 
   
Key safety 
assessments  • Evaluation of all Adverse Events ( AEs) and Serious AEs ( SAEs ) 
• Physical examination  
• Vital signs  
• Laboratory evaluations (e.g. hematology, clinical chemistry) 
  
  
• Pregnancy  
Other 
assessments    
  
Data analysis  In each cohort, for  secukinumab 300 mg and placebo treatment groups,  the 
proportion of subjects classified as IGA responders after 16 weeks of 
treatment, will be modeled with a binomial distribution. A neutral, non-
informative Beta (1/3, 1/3)  distribution will be used as the prior for the 
response rate for secukinumab and placebo treatment  groups. Based on the 
priors and the observed primary outc ome, posterior  distributions for the 
response rate in secukinumab and placebo treatment groups will be 
computed respectively for each cohort. The posterior distribution of the 
difference of response rates  over placebo will be obtained by [CONTACT_102143]. 
The posterior probabilities for a positive treatment difference will be assessed according to the dual efficacy criteria as a guide to decision  making. In each cohort, secukinumab treatment will be assessed 
separately in comparison to the placebo group. Subjects who do not 
complete  the 16 -week treatment  will be considered as non -responders.   
Key words  Lichen planus, LP, CLP, MLP, LPP, IL- 17A, monoclonal antibody, AIN457, 
secukinumab, itch, pain, efficacy, safety  

[COMPANY_001]  Confidential  Page 18  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
1 Introduction 
1.1 Background 
Lichen planus (LP) is a mucocutaneous, inflammatory disease of unknown etiology. First 
described in [ADDRESS_410568] lεixήn, for ‘tree moss’, and the Latin word planus , for ‘planar’, lichen planus is a relatively uncommon and heterogeneous 
disorder that typi[INVESTIGATOR_331935] -aged adults affecting the skin, the mucosae, or both 
(Tziotzios  et al 2018). It is recurrent, and can present in different clinical subtypes based on the 
morphology of the lesions and the site of involvement. 
Skin lesions of lichen planus (cutaneous lichen planus, CLP) are characterized by a subacute or 
chronically progressive appearance of polygonal purple papules often associated with severe itch. Mucosal lesions (mucosal lichen planus, MLP) present with usually bilateral white 
striations or plaques, either symptomatic or extremely painful due to their erosive nature, and localized in different areas (buccal mucosa, tongue and gingivae, genitalia, conjunctiva  or 
esophagus ). Lichen planopi[INVESTIGATOR_22785] (LPP)  is considered a follicular variant of CLP and develops 
with active patches that, if untreated, lead to irreversible scarring and alopecia. LPP has a sexual predilection for females and can also be induced by [CONTACT_331988]-operative immune-inflammatory responses ( Gorouhi et  al 2014).  
Lichen planus (LP) estimated prevalence is in the range of 0.1 to 4 percent of the general population ( Zakrzewska et al 2005). Oral or genital involvement occurs in 60- 70% of patients, 
and it may be the sole manifestation of disease in 20-30% of patients. 
The refractory nature of the disease, and the potential of the lesio n to become erosive, atrophic, 
or even carcinogenic, correlates with patient's poor quality of life because of the associated pain 
and discomfort. A study assessing DLQI ( Balci  and Inandi 2008), reported that patients w ith 
lichen planus describe the impact of the disease on the quality of life comparably to patients 
with psoriasis.  
Histologically, the disease shows apoptosis of keratinocytes, acanthosis, hypergranulosis, vacuolating degeneration of the basal layer of the  epi[INVESTIGATOR_241117] a lymphocytoid, cell-rich 
infiltrate in the upper dermis ( Cassol -Spanemberg et  al 2019). An important entity in the 
differential diagnosis of lichen planus are lichenoid drug reactions, which can be virt ually 
indistinguishable from cutaneous lichen planus both clinically and histopathologically. 
There are no established guidelines for lichen planus treatment, and as yet  the pathogenesis and 
potential therapeutic targets of the disease remain poorly unders tood. Conventional therapi[INVESTIGATOR_331936] 
(CLP) or pain (MLP). Current clinical practice utilizes topi[INVESTIGATOR_76929], retinoids, calcineurin inhibitors (such as cyclosporine, tacrolimus and pi[INVESTIGATOR_031]), and in some cases light therapy.  
Topi[INVESTIGATOR_331937]- line drugs, while systemic 
treatments are reserved for patients with disease that is more widespread, unresponsive to topi[INVESTIGATOR_331938] ( Thongprasom and  Dhanuthai 2008).  
Despi[INVESTIGATOR_331939], the abundance of the lymphocytic T  cell 
infiltrate supports the participation of cellular immunity with both helper and cytotoxic T  cells 
[COMPANY_001]  Confidential  Page 19  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
playing a vital role in its pathogenesis. A delayed hypersensitivity immune reaction, in which 
the release of cytokines by [CONTACT_93247] T  cells leads to the attraction of other immune cells and to 
the destruction of keratinocytes by [CONTACT_79371] -mediated cytotoxicity, has been implicated in the 
pathogenesis of lichen planus ( Shaker  and Hassan  2012).  
Notably, every step mediated by T cells in the pathogenesis of lichen planus is amendable for interruption, and recent innovations in biologic therapi[INVESTIGATOR_331940]. In fact, several anecdotal cases have been described, providing evidence of therapeutic benefit for patients undergoing biologic therapi[INVESTIGATOR_014] ( Zhang  et al 2011).  
Recently, a case report showed the potential of biologic agents targeting the IL -23/Th17 axis to 
induce clinical remission and strong improvements on a cellular/molecula r level in 5 patients 
with steroid refractory lichen planus ( Solimani et  al 2019), corroborating numerous previous 
findings and suggesting a key role for IL -17A in the pathogenesis of lichen planus. It also 
showed the p resence of IL -17A producing Th17 as well as Tc17 cells in lichen planus lesions. 
In fact, several papers described elevated serum concentrations of IL -17A and increased 
numbers of peripheral and lesional Th17 cells in patients with mucocutaneous and oral l ichen 
planus, as well as upregulation of IL -17A and Th17- derived cytokines ( Schmidt et  al 2018, 
Gueiros et  al 2018).  
Secukinumab (AIN457) is a recombinant high- affinity fully human monoclonal anti -human IL -
17A antibody of the immunoglobulin (Ig) G1/κ -class. Secukinumab binds to human IL -17A 
and neutralizes the bioactivity of this cytokine. IL -17A is the central cytokine of a newly defined 
subset of inflammatory T cells, the Th17 cells which, , are pi[INVESTIGATOR_108988]. IL -17A is mainly produced by [CONTACT_109013]4+ and CD8+ T 
lymphocytes and is recognized as one of the principal pro- inflammatory cytokines in immune 
mediated inflammatory diseases.  Its neutralization is expected to treat the underlying 
pathophysiology of immune mediated disease, and as a consequence provide relief of symptoms. 
Secukinumab (Cosentyx
®) with a recommended dose of 300 mg was approved in 2014 in Japan, 
in 2015 in the US, EU and Switzerland for the treatment of moderate to severe plaque psoriasis 
in adults. Secukinumab is also approved for the treatment of adult patients with psoriatic 
arthritis or ankylosing spondylitis. Secukinumab is available as a powder for solution f or 
injection, and as a solution of 150 mg in 1 mL for injection in pre -filled syringe or auto- injector.  
The Investigator’s Brochure (IB 2020 ) provides a more detailed review of the pre -clinical and 
clinical information on secukinumab. 
Secukinumab has proven to be a suitable therapeutic option for immune mediated disorders, 
and based on the available scientific evidence and case reports, secukinumab has the potential to be an effective therapy for patients with moderate to severe lichen planus. 
The aim of th e present study is to assess the efficacy, safety,  and tolerability 
of two dose regimens of secukinumab in patients with moderate to severe lichen planus. 
1.2 Purpose 
The purpose of this proof -of-concept study is to elucidate the efficacy of secukinumab in the 
treatment of adult patients with biopsy -proven lichen planus not adequately controlled by 
[CONTACT_12523][INVESTIGATOR_12491], and to assess the safety and tolerability over 32 weeks. 

[COMPANY_001]  Confidential  Page 20  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
Lichen planus (LP) is a chronic, inflammatory condition affecting different locations of the 
body (skin, oral cavity, genitalia, scalp, and nails), sometimes concomitantly.  
Current therapi[INVESTIGATOR_331941] -spectrum 
immunosuppressive or anti -inflammatory topi[INVESTIGATOR_331942]. However, 30 -50% of 
patients are refractory to current therapi[INVESTIGATOR_331943] a higher burden of disease due to lack 
of clinical control, as well as significant psychological discomfort and social disability resulting in profoundly impaired quality of life.   
These patients may benefit from a systemic, targeted therapy selectively inhibiting IL -17A, a 
key player in the skin inflammatory cascade. This study will evaluate the therapeutic efficacy of secukinumab in treating three well -defined subtypes of lichen planus, for which no systemic 
therapy is currently approved and which could be eligible for treatment with secukinumab. 
2 Objectives and endpoints  
Table 2-1 Objectives and related endpoints  
Objective(s)  Endpoint(s)  
Primary objective(s)  Endpoint(s) for primary objective(s)  
• To demonstrate the clinical efficacy of 
secukinumab 300 mg every 4 weeks (Q4W) in subjects with cutaneous lichen planus (CLP), 
mucosal lichen planus (MLP), or lichen 
planopi[INVESTIGATOR_22785] (LPP) inadequately controlled by [CONTACT_12523][INVESTIGATOR_12491], with respect to improvement in Investigator’s Global Assessment (IGA) score 
by [CONTACT_10585] 16, compared to placebo.  • Achievement of IGA response at Week 16
 
Patients diagnosed with biopsy -proven 
forms of CLP, MLP or LPP will be considered responders if they achieve an absolute IGA  score ≤2 at Week 16
 
Secondary objective(s)  Endpoint(s) for secondary objective(s)  
• The secondary objectives of this trial comprise the foll owing:
 
- evaluate the efficacy of secukinumab 300 mg 
Q4W compared to placebo throughout  16 
weeks  in Treatment Period 1;  
- evaluate the long term efficacy of 
secukinumab 300 mg Q4W throughout  32 
weeks in Treatment Period 2;  
- evaluate the efficacy  of secuki numab 300 mg 
Q2W in Treatment Period 2;  
- evaluate the safety profile of secukinumab 300 
mg throughout  the duration of the study.  
Detailed assessments are described the next 
section.   
All subtypes  
Investigator's Global Assessment (IGA)  • Achievement of  2 points improvement in 
the IGA  score  from baseline to Week 16 
and 32, and throughout the duration of 
the study  
Achievement of IGA 0/1 at Week 16 and 
32, and throughout the duration of the 
study  
[COMPANY_001]  Confidential  Page 21  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
Objective(s)  Endpoint(s)  
• Dermatology Life Quality Index (DLQI)   • Absolute and relative change in DLQI 
from baseline to Week 16 and 32, and throughout the duration of the study
 
Achievement of DLQI 0/1 score at Week 16 and 32, and throughout the duration 
of the study  
• Patient assessment of itch (NRS)  • Absolute and relative change in NRS 
from baseline to Week 16 and 32, and 
throughout the duration of the study  
• Patient assessment of pain (NRS)  • Absolute and relative change in NRS 
from baseline to Week 16 and 32, and 
throughout the duration of the study  
• To assess the safety and tolerability of 
secukinumab in subjects with lichen planus.  • Adverse events, laboratory values, vital 
signs  
Cutaneous Lichen Planus (CLP)   
• Physician Assessment of Surface Area of 
Disease (PSAD) for Skin Disease  • Absolute and relative change in PSAD from baseline to Week 16 and 32, and 
throughout the duration of the study  
Mucosal Lichen Planus (MLP)   
• Reticular Erythematous Ulcerative (REU) score  • Absolute and relative change in REU score from baseline to Week 16 and 32, 
and throughout the duration of the study  
• Oral Lichen Planus Symptoms Severity Measure (OLPSSM) score
 • Absolute and relative change in OLPSSM score from baseline to week 16 and 32, and throughout the duration of 
the study  
Lichen Planopi[INVESTIGATOR_22785] (LPP)   
• LPP Activi ty Index (LPPAI)  • Absolute and relative change in LPPAI score from baseline to Week 16 and 32, 
and throughout the duration of the study  
• SCALPDEX Questionnaire  • Absolute and relative change in SCALPDEX Questionnaire score from 
baseline to Week 16 and 32, and 
throughout the duration of the study  

[COMPANY_001]  Confidential  Page 22  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
3 Study design  
This is a multicenter, randomized, double -blind, placebo- controlled, parallel -group trial 
assessing the efficacy and safety of secukinumab 300 mg in two different dosing regimens in 
patients with biopsy-proven forms of lichen planus. 

[COMPANY_001]  Confidential  Page 23  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
The study consists of three cohorts (one cohort per lichen planus subtype: cutaneous lichen 
planus (CLP), mucosal lichen planus (MLP) and lichen planopi[INVESTIGATOR_22785] (LPP)) and 4 study periods as illustrated in  Figure 3-1. 
Patients are assign ed to one of the three cohorts based on their predominant  subtype and 
undergo a biopsy to confirm the clinical diagnosis at the screening visit: 
• Predominantly cutaneous  lichen planus 
• Predominantly mucosal  lichen planus 
• Lichen  planopi[INVESTIGATOR_331944] 4 periods: • Screening Period : up to 4 weeks prior to baseline 
• Treatment Period 1 : baseline to Week 16  
• Treatment Period 2 : Week 16 to Week 32 
• Follow- up: 8 weeks after Week 32  
Screening period:  
A screening period of up to 4 weeks is used to assess patient´s eligibility for the trial and to 
washout/adjust prohibited medications. The screening period covers the time from the signature [CONTACT_43998]/screening visit (-4 weeks) to the randomization visit (Week 0).  
Patients can be re -screened if the patient fails the initial screening due to a transient condition 
(not related to LP) or due to an insufficient prohibited medication washout period. Subjects can 
be re -screened only once and no re -screening procedure should be performed prior to re -
consenting the subject. Patients may also be rescreened at a later time if site closures or other 
logistical issues prevent randomization as planned. Patients presenting with a reduction in the 
IGA score between screening and baseli ne, with the IGA not qualifying as moderate or severe 
at the baseline visit ( i.e., IGA score of 2, 1 or 0 ), will not be eligible for re -screening. 
Treatment Period 1:  
Treatment Period 1 is placebo -controlled and covers the time from Week 0 (randomization visit) 
to Week 16. Patients who meet all eligibility criteria are randomized in a 2:1 ratio to one of the following two treatment arms within  their cohort: 
• Secukinumab 300 mg every 4 weeks arm : subjects receive a weekly induction treatment 
followed by [CONTACT_37234] 300 mg every 4 weeks. 
• Placebo for 16 weeks followed by [CONTACT_37234] 300 mg every 2 weeks arm:  subjects 
receive matching placebo injections.  
Thirty -six patients w ill be randomized per cohort, 24 to active and 12 to placebo treatment, 
which means that the study will enroll approximately 108 subjects in total. 
In Treatment Period 1 all subjects receive weekly subcutaneous injections of blinded study drug 
(either 300 mg secukinumab or placebo) at weeks 0, 1, 2, 3 and 4. Thereafter the frequency of blinded study drug injections for all subjects is every 4 weeks up to Week 16. Home administration of study drug is not  allowed during Treatment Period 1. Subjects who comple te 
Treatment Period 1 roll over to Treatment Period 2 at the week 16 visit. The only exception are subjects from the placebo for 16 weeks followed by [CONTACT_37234] 300 mg every 2 weeks arm, 
[COMPANY_001]  Confidential  Page 24  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
who achieve spontaneous remission at the Week 16 visit. Spontaneous remission is defined as 
an IGA of 0 or 1 at Week 16. These subjects do not proceed to Treatment Period 2 to avoid 
unnecessary treatment. Instead they will directly enter the Follow -up Period after the Week 16 
visit.  
Treatment Period 2:  
Treatment Period 2 s tarts at the Week 16 visit and covers the time until the Week 32 visit.  
Depending on the treatment arm, subjects receive the following treatments: 
• Secukinumab 300 mg every 4 weeks arm : subjects receive continued treatment with 
secukinumab 300 mg every 4 weeks plus matching placebo injections to maintain 
treatment blinding.  
• Placebo for 16 weeks followed by [CONTACT_37234] 300 mg every 2 weeks arm : subjects 
are switched to active treatment with secukinumab [ADDRESS_410569] injection of Treatment Period 2. 
Treatment remains blinded during Treatment Period 2. This means that , starting at the Week 16 
visit, all subjects rec eive an induction consisting of weekly blinded study drug injections (either 
secukinumab 300 mg or placebo) at weeks 16, 17, 18, 19 and 20, followed by [CONTACT_331989] 2 weeks, either secukinumab 300 mg alternating with placebo every 2 weeks (secukinumab 300 mg every 4 weeks arm) or secukinumab 300 mg every 2 weeks (placebo for 16 weeks followed by [CONTACT_37234] 300 mg every 2 weeks arm) until week 30. 
The last study drug injection is  administered  at Week 30. The end of Treatment Period [ADDRESS_410570] visit of the 
treatment period during which they discontinue (Week 16 or Week 32).  
Subjects , whether they are willing to continue attending further study visits or not, should attend 
the End of Treatment visit (EOT) of the  study period during which they discontinued (EOT 1 
for discontinuation during Treatment Period 1 and EOT 2 for discontinuation during Treatment 
Period 2). EOT1  should be performed [ADDRESS_410571] dose of study drug. See Section 9.1 for further details.  
Follow- up: 
There is an [ADDRESS_410572] discontinues study during Follow-up period, visit Week 40 has to be performed. 
 
 
[COMPANY_001]  Confidential  Page 25  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
Figure 3-[ADDRESS_410573] pathophysiological overlap 
between the three selected subtypes (e.g. dominant role of T  cells, presence of Th17 and Tc17 
cells, overexpression of IL -17A in lesions in an encouraging case report on the use of 
secukinumab in lichen planus; Solimani et  al 2019 ) giving strong evidence for a role of IL -17A 
in the pathophysiology of all three subtypes. Furthermore, there is broad clinical overlap between the three subtypes, especially between CLP and MLP subtypes, with many patients presenting concomitant symptoms and lesions. At the same time each subtype presents at different anatomical regions and with distinct clinical features and symptoms, e.g. ulceration can be present in the mucosal subtype but not in the cutaneous, whereas itching is highly relevant in patients with CLP but not in patients with MLP, or hair follicle inflammation, which is the unique feature of LPP. Patients are divided into three cohorts, according to their predominant  clinical subtype in order to apply subtype- specific assessments. By [CONTACT_331990] -predominant ("concomitant") subtype, 
e.g. data on cutaneous lesions in a patient who is enrolled in the predominantly mucosal lichen 

[COMPANY_001]  Confidential  Page 26  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
planus cohort. This ensures optimal usage of all available patient data. Since clinical sites with 
a special focus on the treatment of lichen planus usually see patients of all [ADDRESS_410574] the opportunity to enroll pa tients of all 
subtypes in one bundled trial. In addition, this "basket trial" approach enables pooled efficacy and safety assessment across all three subtypes.  
The randomization process ensures a comparable and balanced profile of patients across treatment  arms. The reason to have a 2:[ADDRESS_410575] that the safety profile of secukinumab in patients with lichen planus differs from the favorable safety profile observed in the extensive safety database of secukinumab in the currently approved indications (psoriasis, psoriatic arthritis and ankylosing spondylitis). 
Treatment Period [ADDRESS_410576] used comparable durations: Hazra et al. compared systemic betamethasone to methotrexa te for 12 weeks ( Hazra et  al 2013), or enoxaparin was 
compared to methotrexate for 24 weeks ( Lunge et  al 2016).  
During Treatment Period 2, subjects who have been on active treatment in Treatment Period 1 receive continued active treatment in the same dosing regimen (secukinumab 300 mg every 4 
weeks) until Week 32. This allows the collection of longer term efficacy and safety data beyond [ADDRESS_410577] been on placebo treatment in Treatment Period 1 are switched to active treatment with secukinumab 300 mg every 2 weeks (starting with the regular weekly induction). This enables placebo treated patients to receive active treatment during the trial as well. Furthermore it allows the assessment of effic acy and safety of the 2- weekly dosing 
regimen in lichen planus. Subjects randomized to the placebo arm who achieve spontaneous clinical remission, which is defined as an IGA of 0 or 1, do not roll over to Treatment Period 2, 
instead they directly enter the  Follow- up Period. The rationale for this is to avoid unnecessary 
treatment for these patients in Treatment Period 2. A n IGA of 0/[ADDRESS_410578] that this is an early, proof -of-concept study, 
this limitation can be considered as acceptable.  
The secukinumab 300 mg every 4 weeks dosing regimen is given to subjects in the active treatmen t arm in Treatment Period 1, while the higher dosing regimen, secukinumab 300 mg 
every 2 weeks, is explored in Treatment Period 2 in subjects switching over from placebo. This 
[COMPANY_001]  Confidential  Page 27  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
design enables every participating subject to receive active treatment and makes  the trial 
efficient by [CONTACT_331991] 4 weeks dosing regimen versus placebo, while 
additionally giving the opportunity to explore the higher dosing regimen, secukinumab 300 mg every 2 weeks, without having to add an additional treatment arm. 
Treatment blinding is maintained beyond the primary endpoint (week 16) throughout Treatment 
Period 2, which enables cross -comparison of the sequential efficacy and safety data of the 2-
weekly dosing regimen in Treatment Period [ADDRESS_410579] the opportunity to assess if the continued participation in the trial is to the patient´s benefit. If the subject´s participation is deemed not to be of benefit for the subject, she/he can exit the trial at any time. 
4.2 Rationale for choice of background therapy 
Patients entering the trial will be allowed to use topi[INVESTIGATOR_12491] (low -moderate potency 
corticosteroids, Over the Counter (OTC) emollients and lubricants or mouthwash for pain; please see Section  6.2.1 for details) as background treatment in both arms. The primary reason 
for this is to alleviate the symptom burden of subjects receiving placebo treatment during the first 16 weeks of the study. Especially in patients with mucosal/ oral lichen planus, symptoms caused by [CONTACT_331992] (topi[INVESTIGATOR_11930], local anesthetics etc.) is important for the adequate management of these patients. The allowed background treatments are  typi[INVESTIGATOR_331945] ( Husein -ElAhmed  et al 2019; Tziotzios  et al 2018; 
Le Cleach  and Chosidow 2012) (see Section  6 for details). Although it is a key inclusion 
criterion for patients to be inadequately controlled by [CONTACT_12523][INVESTIGATOR_12969], this does not mean that the patients do not benefit from topi[INVESTIGATOR_331946]. The allowed topi[INVESTIGATOR_331947]´ symptoms to a certain degree and may limit further progression of the disease.  
  
 
  
  
    
 
 

[COMPANY_001]  Confidential  Page 28  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 
 
         
 
   
 
 
  
 
         
 
  
 
       

[COMPANY_001]  Confidential  Page 29  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 
 
4.[ADDRESS_410580] moderate to severe lichen planus inadequately controlled by [CONTACT_12523][INVESTIGATOR_12491]. In this "second line" setting, systemic treatments are indicated. However, there are very few systemic treatments having proven clinical efficacy and safety in adequately powered, randomized,  
controlled trials. Systemic corticosteroids, retinoids, cyclosporin, methotrexate or hydroxychloroquine are options, but often characterized by [CONTACT_331993] ( Thandar et al 2019).  
To minimize patients´ burden, the duration of placebo treatment is limited to 16 weeks and topi[INVESTIGATOR_331948], local anesthetics  or corticosteroids of low to moderate 
potency are allowed as background therapy in both arms (see Section  6.2.1 for details). 
Although it is an inclusion criterion of this trial to be inadequately controlled by [CONTACT_12523][INVESTIGATOR_331949] 30  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
treatments, this does not mean that patients do not derive any benefit from topi[INVESTIGATOR_12969]. 
The allo wed topi[INVESTIGATOR_331950], still alleviate patients´ 
symptoms to a certain degree and may prevent further worsening of the disease that might occur without them. Continued topi[INVESTIGATOR_72049] 16 weeks is not considered a m ajor safety risk 
for this patient population. Furthermore, randomization is done in a 2:1 ratio to reduce the number of patients under placebo treatment. After Week 16, all patients originally randomized to placebo, except those with spontaneous remission, are switched to active treatment with 
secukinumab 300 mg every 2 weeks, so all patients entering the trial receive active treatment, either starting at baseline or at Week 16. Since patients switching from placebo to active treatment are receiving secukin umab 300 mg every 2 weeks in Treatment Period 2, and patients 
who started with active treatment in Treatment Period 1 receive secukinumab 300 mg every 4 weeks throughout both treatment periods, the  cumulative  dose of secukinumab each patient 
population receives differs by [INVESTIGATOR_13701] 10% (3300 mg for patients initially randomized to active treatment vs. 3000 mg for patients initially randomized to placebo). Furthermore if the patient´s participation in the trial is not considered to be of benefit for the patient by [CONTACT_331994] -/himself, or the patient requires a different therapy than the one offered in the 
trial, she/ he can exit the trial at any time.  
4.5 Purpose and timing of interim analyses/design adaptations 
A primary endpoint analysis is planned to be conducted either once all patients have completed the Week [ADDRESS_410581] completed the Week 16 visit. This will be decided depending on the recruitment of the 3 cohorts. The purpose of this prima ry endpoint analysis is to assess whether secukinumab shows efficacy and safety in the 
selected lichen planus subtypes at an early time point (proof of concept). This enables planning of further clinical development of secukinumab in lichen planus. At the end of the study, the final analysis of all data collected will be performed once all patients have completed their last study visit. All patients, investigators and site personnel will remain blinded until final database lock. 
Further analyses are current ly not planned. However, an unscheduled analysis could be 
conducted if a compelling reason arises, for example, if requested by [CONTACT_21652]. 
4.[ADDRESS_410582] clinical 
evidence (case series by [CONTACT_331995] 2019), IL -17A plays a key role in the pathophysiology 
of lichen planus and secukinumab, which is directed against IL -17A, therefore has the potential 
to reduce disease activity and improve symptom severity in patients with lichen planus. 
Moreover, given the extensive exposure and the well -established and favorable safety profile 
of secukinumab in patients with moderate to severe plaque -psoriasis, [COMPANY_001] is not aware of 
any medical/scientific evidence that would indicate potential differ ences in the safety profile of 
secukinumab between the psoriasis and the lichen planus patient populations. Secukinumab´s currently approved dosing (300 mg given every 4 weeks) showed a consistent 
and favorable safety profile across a large clinical develo pment program and extensive post -
[COMPANY_001]  Confidential  Page 31  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
marketing experience since its first approval for moderate to severe plaque- psoriasis in 2015. 
Approximately 4,000 patients with moderate to severe plaque -psoriasis were included in the 
studies of the registration program. This included 3,430 subjects treated with secukinumab in 
10 phase II/III studies, 2,[ADDRESS_410583] 48 weeks. Details of the risks and benefits are outlined in the current version of the Investigator's Brochure. The safety data from the completed and ongoing studies including AE and SAE data, laboratory parameters and immunogenicity data demonstrate a favorable safety profile. Observed risks include infections, in particular, upper r espi[INVESTIGATOR_67705], neutropenia and hypersensitivity reactions that can be seen with administration of foreign proteins. Most of the infections were non- serious, mild to moderate in severity, 
clinically easily manageable and did not lead to treatment discontinuation. Cases of neutropenia were uncommon, generally mild to moderate and transient and did not lead to treatment discontinuation, and only a few cases were temporally associated with non -serious infections. 
Subjects with pre -existing maligna ncies within the past [ADDRESS_410584] 24 weeks. Furthermore the 300 mg every 2 weeks dosing regimen is currently being evaluated in two Phase 3 trials in patients with hidradenitis suppurativa ([STUDY_ID_REMOVED], [STUDY_ID_REMOVED]) and in a Phase 3 trial in patients with moderate to severe plaque -psoriasis and a body weight ≥ 90 kg 
([STUDY_ID_REMOVED]). The safety profile observed in the data available to date is consistent with the known safety profile of secukinumab and no new safety concerns have been identified. Furthermore, secukinumab has been administered intravenously at a dose of 10 mg/kg body weight either short - or long- term in a number of clinical studies that enrolled patients with 
psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis or multiple sclerosis. The majority of patients was receiving 3 doses of 10 mg/kg i.v. over 1 month (Weeks 0, 2 and 4) and 38 patients with multiple sclerosis were receiving monthly 10 mg/kg i.v. doses for at least six months. Chronic, monthly treatment with secukinumab 10 mg/kg i.v. results in a monthly exposure that is approximately 2- fold higher compared to 300 mg s.c. every 2 weeks dosing 
(the bioavailability of secukinumab administered subcutaneously is 73%). No new or changed safety risks were observed with chronic i.v. treatment compared to the known safety profile of secukinumab with the approved doses. Comparisons across indications are valid given there are no clinically relevant differences in the pharmacokinetic profile of secukinumab observed between the various immune -mediated diseases studied (psoriasis,  psoriatic arthritis, 
ankylosing spondylitis, rheumatoid arthritis, multiple sclerosis, Crohn’s disease, non-infectious uveitis). Additional information can be found in the IB for secukinumab. 
The risk to subjects in this trial is also minimized by [CONTACT_331996], as well as close clinical monitoring. Women of child bearing potential must be informed that taking the study treatment may involve unknown risks to the fetus if pregnancy were to occur during the study, and agree that in order to participate  in the study they must 
adhere to the contraception requirements outlined in the exclusion criteria. If there is any question that the subject will not reliably comply, they should not enter or continue in the study. 
[COMPANY_001]  Confidential  Page 32  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
The highly bothersome symptoms of pain or severe itching ( Welz-Kubiak et  al 2017), the 
significant impact moderate to severe lichen planus has on patient ’s quality of life including 
depression ( Radwan -Oczko  et al 2018; Cheng et  al 2017; Welz-Kubiak et al 2017) and the 
very limited availability of effective and safe systemic treatment options for these patients 
inadequately controlled by [CONTACT_12523][INVESTIGATOR_331951] a high degree of unmet medical need in the treatment of lichen planus. The established and favorable safety profile of secukinumab in moderate to severe plaque- psoriasis and the potential of secukinumab to reduce disease activity 
and improve symptom severity in patients with lichen planus, suggest that participation in this trial offers a well justifiable benefit- risk profile.  
5 Population 
Approximately 108 subjects with biopsy- proven lichen planus will be randomized in the study 
and assigned to  3 cohorts according to their predominant lichen planus subtype (predominantly 
cutaneous lichen planus, predominantly mucosal lichen planus or lichen planopi[INVESTIGATOR_22785]).  
Each cohort will enroll 36 patients randomized in a 2:1 ratio (24 patients will enter the active 
arm, 12 patients the placebo arm). 
Drop -outs after randomization will not be replaced. 
5.[ADDRESS_410585] meet all  of the following criteria:  
1. Written informed consent must be obtained before any ass essment is performed.  
2. Female and male patients ≥ [ADDRESS_410586] biopsy-confirmed forms of cutaneous lichen planus (CLP), mucosal 
lichen planus (MLP), or active lichen planopi[INVESTIGATOR_22785] (LPP) eligible for systemic therapy 
based on the follow ing criteria: 
• rated IGA of ≥ 3 at screening and baseline (moderate or severe) AND  
• inadequate response to topi[INVESTIGATOR_331929]-ultrahigh potency in the opi[INVESTIGATOR_8574]. 
4. If using any of the allowed topi[INVESTIGATOR_331952], the dose and application frequency should remain stable for 2 weeks prior to randomization and until Week 16.  
5.2 Exclusion criteria 
Subjects meeting any of the following criteria are not eligible for inclusion in this study. 
1. Clinical history suspi[INVESTIGATOR_331931]. 
2. Lichen planus pi[INVESTIGATOR_331932]. 
3. Clinical pi[INVESTIGATOR_331953]. 
4. Subjects whose lich en planus is a predominantly bullous variant. 
5. Mucosal LP of the oral cavity or gastrointestinal involvement requiring the patient to use 
parenteral nutrition or feeding tube. 
6. Clinical pi[INVESTIGATOR_331954].  
[COMPANY_001]  Confidential  Page 33  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
7. Clinical pi[INVESTIGATOR_331955]- out cicatricial alopecia (alopecia of Brocque).  
8. Patients diagnosed with frontal fibrosing alopecia (FFA) without active patches of LPP. 
9. Clinical pi[INVESTIGATOR_331956] 3 or more systemic 
immunosuppressive or immunomodulatory agents (e.g. systemic steroids, hydroxychloroquine, cyclosporine, methotrexate and mycophenolate mofetil). 
10. Currently enrolled in any other clinical trial involving any investigational agent or device. 
11. Previous exposure to any other biologic drug directly targeting IL -17A or IL-17RA (e.g. 
secukinumab, ixekizumab or brodalumab) or IL-23/p19 (e.g. tildrakizumab, guselkumab, risankizumab). 
12. Diagnosis of active infectious diseases of the skin, scalp or mucosa (for example bacterial, viral or fungal infections of the mouth) that may interfere with the assessment of the study disease or require treatment with prohibited medications. 
13. Diagnosis of active inflammatory diseases of the skin, scalp or mucosa other than lichen planus that may interfere with the as sessment of the study disease or require treatment 
with prohibited medications. 
14. Presence of any other skin condition that may affect the evaluations of the study disease. 
15. Underlying conditions (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal - e.g., Inflammatory Bowel Disease ) and/or presence of laboratory abnormalities which in the 
opi[INVESTIGATOR_108989]/or places the subject at unacceptable risk for receiving an immunomodulatory therapy. 
16. Current, severe, progressive or uncontrolled diseases that render the patient unsuitable for the trial, including any medical or psychiatric condition that, in the Investigator’s opi[INVESTIGATOR_1649], would preclude the participant from adhering to the protocol or completing the study per protocol. 
17. Ongoing use of ANY treatment prohibited by [CONTACT_760] (for details, refer to  Table 6 -2. 
18. Plans for administration of live vaccines during the study period or within 6 weeks before 
randomization. 
19. Pregnant or nursing (lactating) women. 
20. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using methods of contraception during the entire study or longer if required by [CONTACT_109016] (e.g. in European Union (EU) 20 weeks).  
Contraception methods include: 
• Total abstinence, when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. 
• Female sterilization (have had surgical bilateral oophorectomy [with or without hysterectomy], total hysterectomy or tubal ligation at least six weeks before taking study treatment). In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_6492]-up hormone level assessment. 
• Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that patient. 
[COMPANY_001]  Confidential  Page 34  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
• Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault caps).  
• Use of oral (estrogen and progesterone), injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception or placement of an intrauterine device (I UD) or intrauterine system 
(IUS).  
In case of use of oral contraception, women should have been stable on the same pi[INVESTIGATOR_6522] a minimum of 3 months before taking study treatment. 
In case local regulations deviate from the contraception methods listed above, l ocal 
regulations apply and will be described in the informed consent form (ICF). 
Note: Women are considered post -menopausal and not of childbearing potential if they 
have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical 
profil e (e.g. age appropriate, history of vasomotor symptoms) or have had surgical 
bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks prior to enrollment. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_6492]-up hormone level assessment is she considered not of childbearing potential. 
21. History of recurrent bacterial infection (at least 3 major infections resulting in hospi[INVESTIGATOR_5478]/or requiring intravenous antibiotic treatment within the past 2 years).  
22. History of congenital or acquired immunodeficiency (eg, Common Variable Immunodeficiency [CVID]).  
23. Hepatitis B surface antigen (HBsAg) positive or Hepatitis B core antibody positive at screening.  
24. History of Human Immunodeficiency Virus (HIV) infection. 
25. Hepatitis C antibody positive at screening unless viral load is 0. 
26. Evidence of tuberculosis infection as defined by a positive QuantiFERON
® TB-Gold test 
(QFT) at screening. Patients with a positive or indeterminate QFT test may participate in the study if a full tuberculosis work-up (according to local practice/guidelines) completed within [ADDRESS_410587] 5 years, regardless of whether there is  evidence of local recurrence or metastases (except for skin Bowen’s disease, or 
basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed). 
28. No additional exclusions may be applied by [CONTACT_093], in order to ensure that the study population will be representative of all eligible patients.  
[COMPANY_001]  Confidential  Page 35  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
6 Treatment  
6.1 Study treatment 
The following investigational drug and comparator will be supplied and appropriately labeled 
by [CONTACT_5343]: 
• Investigational drug:  Secukinumab 300 mg, provided as 2 s.c. injections of 1 ml prefilled 
syringe (PFS). Each 1 ml syringe contains 150 mg secukinumab. 
• Comparator:  Placebo, provided as 2 s.c. injections of 1 ml prefilled syringe (PFS). 
Each placebo pre -filled syringe contains a mixture of inactive excipi[INVESTIGATOR_840], matching the 
composition and the appearance of the secukinumab 150 mg dose. 
6.1.1  Investigational and control drugs  
Table 6-1 Investigational and control drug  
Investigational/Co
ntrol Drug  
(Name [CONTACT_6673])  Pharmaceutical Dosage Form  Route of Administration  Supply Type  Sponsor (global or local)  
Secukinumab 
150mg  Solution for subcutaneous 
injection  Subcutaneous injection  Double blind supply, 1ml pre-
filled syringe  Sponsor (global)  
Placebo 150mg  Solution for subcutaneous 
injection  Subcutaneous injection  Double blind supply, 1ml pre-
filled syringe  Sponsor (global)  
Secukinumab and the secukinumab matching placebo will be labeled as “AIN457 150 mg / 
Placebo” (1 ml) to keep the blind. Subjects will initially be instructed on how to perform the injection  by [CONTACT_6624]. They will also receive written instructions as to how to self -inject using 
the pre- filled syringe.  
Patients or caregivers not able/willing to self -administer the drug and perform home 
administration, will be allowed to return to the site for administration of the medication. Dur ing 
those visits, no additional assessments will be performed. 
6.1.2  Additional study treatments  
No other treatments beyond investigational drug, placebo and allowed concomitant topi[INVESTIGATOR_73211]/background treatment are included in this trial. 
6.1.3  Treatment arms/g roup  
According to their diagnosis, subjects will be assigned at Screening visit to one of the following 
cohorts based on the predominant  subtype of the disease (e.g. skin lesions are clinically 
dominant and the primary reason for treatment: patient is assi gned to the cutaneous lichen 
planus cohort; mucosal lesions are clinically dominant and the primary reason for treatment: patient is assigned to the mucosal lichen planus cohort): 
• Cutaneous lichen planus  
[COMPANY_001]  Confidential  Page 36  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
• Mucosal lichen planus  
• Lichen planopi[INVESTIGATOR_331957] (e.g. concomitant presence 
of skin and mucosal lesions) will be eligible to enter the trial provided the cohort assignment occurs following the predominant subtype. 
Within each cohort patie nts will be randomized to one of the treatment arms in a 2:1 ratio: 
• Cutaneous lichen planus  (n=36)  
• Secukinumab 300 mg every 4 weeks (n=24) 
• Placebo for 16 weeks followed by [CONTACT_37234] 300 mg every 2 weeks (n=12) 
• Mucosal lichen planus  (n=36)  
• Secukinumab 300 mg every 4 weeks (n=24) 
• Placebo for 16 weeks followed by [CONTACT_37234] 300 mg every 2 weeks (n=12) 
• Lichen planopi[INVESTIGATOR_22785]  (n=36)  
• Secukinumab 300 mg every 4 weeks (n=24) 
• Placebo for 16 weeks followed by [CONTACT_37234] 300 mg every 2 weeks (n=12) 
 Treatment is divided into 2 treatment periods:  
Treatment Period 1: Week 0 -16 
• Patients in the active secukinumab 300 mg every 4 weeks treatment arm  
receive induction with secukinumab 300 mg s.c. at Weeks 0, 1, 2, 3, 4 and then 
secukinumab 300 mg s.c. every 4 weeks, meaning at Weeks 8 and 12. 
• Patients in the placebo for 16 weeks followed by [CONTACT_37234] 300 mg every 2 weeks treatment arm  receive corresponding placebo injections s.c. at Weeks 0, 1, 2, 3, 4 and 
then every 4 weeks, meaning at Weeks 8 and 12. 
Treatment Period 2: Weeks 16 -32 
• Patients in the active secukinumab 300 mg every 4 weeks treatment arm stay on secukinumab 300 mg every 4 weeks, meaning they receive secukinumab 300 mg s.c. at Weeks 16, 20, 24 and 28. In order to maintain the blinding they additionally receive  placebo injections at Weeks 17, 18 and 19 as well as placebo injections at Weeks 22, 26 and 30. 
• Patients from the placebo  with switch to secukinumab [ADDRESS_410588] injection (secukinumab 300 mg or placebo) is given in both the treatment arms at week 30. 
6.1.[ADDRESS_410589]. 
[COMPANY_001]  Confidential  Page 37  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
6.2 Other treatment(s) 
6.2.[ADDRESS_410590] be recorded in the case report form (CRF).  
The medications listed below are allowed for use throughout the duration of the trial: subjects should be on a stable dose and applica tion frequency of topi[INVESTIGATOR_12969] 2 weeks prior 
to randomization. Administration should remain stable regarding dose and application frequency during Treatment Period 1 (until Week 16) , and it is strongly recommended to 
maintain it at a stable level dur ing Treatment Period 2 (from Week 16 until Week 32).  
The following topi[INVESTIGATOR_153818]:  
• Low- moderate potency corticosteroids  (Group IV, V, VI and VII  as per WHO 
definition): 
Desoximetasone cream, 0.05% Fluocinolone acetonide ointment, 0.025% 
Fludroxycortide ointment, 0.05% 
Hydrocortisone valerate ointment, 0.2% 
Triamcinolone acetonide cream, 0.1% 
Betamethasone dipropi[INVESTIGATOR_322415], 0.02% 
Betamethasone valerate cream, 0.1%  
Fluocinolone acetonide cream, 0.025% 
Fludroxycortide cream, 0.05% 
Hydrocortisone butyrate cream, 0.1%  Hydrocortisone valerate cream, 0.2%   
Triamcinolone acetonide lotion, 0.1% Betamethasone valerate lotion, 0.05% 
Desonide cream, 0.05% 
Fluocinolone acetonide solution, 0.01% Dexamethasone sodium phosphate cream, 0.1% 
Hydr ocortisone acetate cream, 1%  
Methylprednisolone acetate cream, 0.25% 
Triamcinolone acetonide oral rinse, 0.1% 
The paste formulation of a corticosteroid is considered of comparable potency to its ointment 
formulation if the concentration is the same.  The gel formulation of a corticosteroid is 
considered of comparable potency to its lotion formulation if the concentration is the same.  
• OTC emollients,  shampoos and lubricants for the treatment of itch and/or pain,  e.g. 
anti-itch lotions containing menthol, pramoxine or antihistamines  
• (Mixed ) medication for the treatment of  oral pain (e.g., lubricants, OTC mouthwashes 
containing diphenhydramine, viscous lidocaine, antacid, nystatin or corticosteroids of 
Group IV, V, VI and VII  as per WHO definition)  
[COMPANY_001]  Confidential  Page 38  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 
Each concom itant drug must be individually assessed against all exclusion criteria/prohibited 
medication. If in doubt, the investigator should contact [CONTACT_30791] a subject or allowing a new medication to be started. If the subject  is already 
enrolled, contact [CONTACT_331997].  
All other forms of topi[INVESTIGATOR_331958] 3 LP subtypes are not allowed during the 
Screening and Treatment periods. All medications, p rocedures, and significant non- drug 
therapi[INVESTIGATOR_014] (including physical therapy and blood transfusions) administered after the subject was enrolled in the study must be recorded on the appropriate CRF s.  
6.2.[ADDRESS_410591] should discontinue the use of the prohibited treatment if he/she wishes to continue in the study. In case of undue safety risk for the subject, the subject should discontinue study 
treatment at the discretion of the investigator.  
Table 6-2 Prohibited medication  
Medication  Washout period before 
randomization  Note  
Ustekinumab  24 weeks    
Etanercept  4 weeks    
Biological agents targeting IL-
17A or IL- 17RA (e.g. 
ixekizumab, brodalumab)  No prior use allowed    
Biological agents targeting IL-
23/p19 (e.g. guselkumab, 
risankizumab, tildrakizumab)  No prior use allowed    
Systemic, biological 
immunomodulating agents other than above (e.g. agents directed against TNFα such as adalimumab, infliximab, 
certolizumab)  12 weeks    
[COMPANY_001]  Confidential  Page 39  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
Medication  Washout period before 
randomization  Note  
Systemic, non -biological 
immunomodulating treatments 
(e.g. met hotrexate, apremilast, 
systemic corticosteroids, cyclosporine, cyclophosphamide, 
sulphasalazine, azathioprin, 
mycophenolate mofetil, 
dapsone, hydroxychloroquine)  4 weeks    
Finasteride , dutasteride  4 weeks    
PPARγ agonists (e.g. 
pi[INVESTIGATOR_051]), naltrexone,  
doxycycline  4 weeks    
Systemic use of griseofulvin or  
itraconazole  4 weeks    
Retinoids  4 weeks    
Low-level light therapy  4 weeks    
Phototherapy (e.g. UVB)  4 weeks    
Photochemotherapy (e.g. 
psoralen and UVA (PUVA))  4 weeks    
Topi[INVESTIGATOR_22726] 
(cyclosporin, tacrolimus, 
pi[INVESTIGATOR_031]) or topi[INVESTIGATOR_26445] 
D analogues  4 weeks    
Topi[INVESTIGATOR_331959] 
- ultrahigh potency  (group I, 
II, III as per WHO definition)   [ADDRESS_410592] to be switched to the low - moderate 
potency  corticosteroids (group 
IV, V, VI and VII per WHO 
definition) given in 
Section 6.2.1 . Subjects should 
be on a stable dose an d 
application frequency of the low 
- medium potency 
corticosteroids 2 weeks prior to 
randomization. Administration 
should remain stable regarding dose and application frequency during Treatment Period 1 (until Week 16), and it is 
strongly recommended to 
maintain it at a stable level during Treatment Period 2 
(from Week 16 until Week 32).   
Topi[INVESTIGATOR_22724] 4 
inhibitors (e.g. crisaborole)  4 weeks    
Intralesional corticosteroid injection  4 weeks    
Depot corticosteroid injection  6 weeks   
[COMPANY_001]  Confidential  Page 40  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
Medication  Washout period before 
randomization  Note  
Live virus  vaccinations  6 weeks    
Any investigational treatment or 
participation in any 
interventional  trial 4 weeks or 5 half -lives, 
whichever is longer    
6.2.3  Rescue medication  
Use of rescue medication is not permitted in this study. Regarding the use of topi[INVESTIGATOR_331960], please see previous ( section 6.2.1 and  section 6.2.2).  
6.[ADDRESS_410593] Number (Subject No.), that is assigned when the subject is first enrolled for screening and is retained as the primary identifier for the subject throughout his/her entire participation in the trial. The Subject No. consists of the Center Number (Center No., as assigned by [CONTACT_331998]) with a sequential subject 
number suffixed to it, so that each subject is numbered uniquely across the entire database. Upon signing the informed consent form, the subject is assigned to the next sequential Subject No. available.  
The investigator or his/her staff will contact [CONTACT_331999] (IRT) and provide the reque sted identifying information for the subject to register them into the IRT.  
If the subject fails to be treated for any reason, the IRT must be notified within [ADDRESS_410594] was not treated. The reason for not being treated will be entered on the appropriate eCRF.  
6.3.2  Treatment assignment, randomization  
At the baseline visit,  all eligible subjects will be randomized via Interactive Response 
Technology (IRT) to one of the treatment arms. The investigator or his/her delegate will contact [CONTACT_332000]/exclusion criteria. The IRT 
will assign a randomization number to the subject, which will be used to link the subject to a treatment arm and will specify a unique medication number for the first package of study treatment to be dispensed to the subject. 
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from subjects and investigator staff. A subject randomization list will be produced by [CONTACT_6609] a validated system that automates the random assignment of subject numbers to randomization numbers. These randomization numbers are linked to the different treatment arms, which in turn are linked to medication numbers. A separate medication list will be produced by [CONTACT_332001] (GCS) using a validated system that automates the random assignment of medication numbers to packs containing the study treatment. 
All effic acy and safety assessments should be done prior to calling IRT.  
[COMPANY_001]  Confidential  Page 41  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
The randomization scheme for subjects will be reviewed and approved by a member of the 
Randomization Office.  
6.4 Treatment blinding 
This is a double blind study. Subjects, investigator staff, persons performing the assessments, and clinical trial team (CTT) will remain blind to the identity of the treatment from the time of 
randomization until database lock, using the following methods: 
(1) Randomization data are kept strictly confidential until th e time of unblinding and will not 
be accessible by [CONTACT_131551]: 
• Specific members whose role in trial conduct requires their unblinding (e.g., IRT, 
designated Unblinded Data manager (if needed)) 
• Global Clinical Supply 
• Designated [COMPANY_001] study team members involved in the primary endpoint analysis 
(2) the identity of the treatments will be concealed by [CONTACT_332002], labeling, schedule of administration, appearance, taste, and odor. 
  
 
Unblinding will occur in the case of subject emergencies and at the conclusion of the study. 
6.[ADDRESS_410595] eCRF page (visit specific and summary pages). For study treatment administration at home, the investigator must promote compliance by [CONTACT_332003] 42  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
for the subject’s safety and the validity of the study. The subject must also be instructed to 
contact [CONTACT_087]/she is unable for any reason to administer the study treatment.  
All study treatment dispensed and returned must be recorded in the Drug Accountability Log. 
Compliance will also be assessed and confirmed by a field monitor by [CONTACT_332004], by [CONTACT_332005], administration and accountability. Cross-checks should be performed for home administrations (H) and empty medication outer packing and subject's returned PFS should be collected for compliance checks by [CONTACT_332006]. This information should be captured in the source document at each visit.  
 
 
6.6.[ADDRESS_410596] -of-care and is at the 
discretion of the investigator or treating physician. There are no specif ic treatment 
recommendations for adverse events that may possibly occur in this trial. Refer to the Investigator's Brochure for adverse events related to secukinumab. 
Medication used to treat adverse events (AEs) must be recorded on the appropriate CRF.  
6.6.[ADDRESS_410597], he/she must provide the requested subje ct identifying information and confirm the necessity to break the treatment code 
for the subject. The investigator will then receive details of the investigational drug treatment for the specified subject and a fax or email confirming this information. The  system will 
automatically inform the [COMPANY_001]  monitor for the site and the study team that the code has been 
broken. 
It is the investigator’s responsibility to ensure that there is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emergency. The investigator will provide: 
• protocol number 
• study drug name 
• subject number 
In addition, oral and written information must be provided to the subject on how to contact 
[CONTACT_5657]/her backup in cases of emergency, or when he/s he is unavailable, to ensure that un-blinding 
can be performed at any time.  
Study drug must be discontinued after emergency unblinding. 

[COMPANY_001]  Confidential  Page 43  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
The appropriate personnel from the study site and [COMPANY_001] will assess whether study treatment 
should be discontinued for any subjects whose treatment code has been broken inadvertently for any reason. 
6.[ADDRESS_410598] by [CONTACT_105245](s). The study medication has a 2- part label (base 
plus tear -off label). Immediately before dispensing the medication kit to the subject, site 
personnel will detach the outer part of the label from the packaging and affix it to the source document. 
In the event of a major health care disruption (e.g., pandemic, epid emic ) that limits or prevents 
on-site study visits , study drug may be shipped or provided directly to patients for home 
administration if needed . The shipment /provisioning will be for a maximum quantity covering  
a 4-month supply. In this case, regular phone calls (every 4  weeks or more frequently, if needed ) 
will occur between the site and the patient  for instructional purposes, safety monitoring and 
discussion of the patient´s health status until the patient can agai n visit the site.  
6.7.1  Handling of study treatment and additional treatment  
[IP_ADDRESS]  Handling of study treatment  
Study treatment must be received by a designated person at the study site, handled and stored 
safely and properly and kept in a secured location to which only the investigator and designated site personnel have access. Upon receipt, all study treatment must be stored according to the instructions specified on the labels and in the Investigator’s Brochure. Clinical supplies are to be dispensed only in accordance with the protocol. Technical complaints are to be reported to the respective [COMPANY_001] Country Organization ( CO) Quality Assurance. 
Medication labels will be in the local language and comply with the legal requirements of each country. They will include storage conditions for the study treatment but no information about the subject except for the medication number . 
The investigator must maintain an accurate record of the shipment and dispensing of study treatment in a drug accountability log. Monitoring of drug accountability will be performed by [CONTACT_332007]. Subjects will be asked 
to return all unused study treatment and packaging at the end of the study or at the time of discontinuation of study treatment. 
At the conclusion of the study, and as appropriate during the course of the study, the investigator 
will return all unused study treatment, packaging, drug labels, and a copy of the completed drug accountability log to the [COMPANY_001] monitor or to the [COMPANY_001] address provided in the investigator folder at each site.  
[COMPANY_001]  Confidential  Page 44  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
[IP_ADDRESS]  Handling of additional t reatment  
Not applicable 
6.7.2  Instruction for prescribing and taking study treatment  
Secukinumab solution for s.c. injection or placebo secukinumab solution (active or placebo, 
respectively) will be provided in pre- filled syringes (PFS).  
Each subject will receiv e one box per visit throughout the study. Each box will contain: 
• two 1ml PFS of secukinumab 150 mg OR  
• two 1ml PFS of secukinumab/placebo [ADDRESS_410599] study treatment administration will occur at the baseline/randomization visit after the 
inclusion/exclusion criteria have been confirmed and all scheduled study assessments have been performed. All study assessments, including completion of Patient Reported Outcomes (PROs) and blood withdrawal, should be completed prior to the self- injection of study treatment.  
All doses of study treatment (secukinumab and/or placebo) will be self -administered by [CONTACT_1560]/ trained caregiver either at the study sit e after the study assessments for the visits have 
been completed or at home.  
The first use at baseline and the Week [ADDRESS_410600] via the pre -filled 
syringe (Instructions for Use (IFU) containing detailed information about self -administration of 
study treatment should be provided to each subject at the beginning of the study). After providing detailed explanations/instructions, subjects will then be asked to raise any questions. Thereafter, they will proceed with self -injection.  
Home administrations (H) should be done at pre -defined visits (se e Section  3). Home 
administration can be performed by [CONTACT_37247]. If the subject or caregiver is not able/confident to perform home administration, the subject will be allowed to return to the site for adm inistration of the medication. However, during those visits no additional 
assessments will be required.   
In case of a major health care disruption (e.g., pandemic, epi[INVESTIGATOR_901] ) that limits or prevents  
on-site study visits,  home administration of the study drug is generally permitted. Home 
administration can be performed by [CONTACT_76409] a trained caregiver. S tudy participants or 
caregivers will be trained adequately on how to perform administrations of the study treatment, 
if not already trained. If the patient or caregiver is not trained for drug administration and cannot visit the site to undergo training, the site can consider providing suitable virtual training and oversight. A joint decision together with the patient or caregiver should be made as to whether this constitutes sufficient training and oversight.  
During home administrations, subjects will be instructed to contact [CONTACT_093]/site staff in 
case they are experiencing any AE/SAEs or have any concerns.  
Administration  
[COMPANY_001]  Confidential  Page 45  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
The study treatment solution must be injected in  non- affected  areas of the skin.  
Pre-filled syringes should be kept at 2 to 8°C (36°F and 46°F), never be frozen, and should be 
protected from light. Prior to administration, the boxes containing the pre- filled syringes should 
be allowed to adapt to room temperature unopened for about 20 minutes before administration. 
Used PFS (if according to the regulatory needs of the respective countries) should be stored in the original boxes and returned at the next site visit for reconciliation  
All kits of study treatment assigned by [CONTACT_6607]. 
7 Informed consent procedures  
Eligible subjects may only be included in the study after providing (witnessed, where required by [CONTACT_6617]), IRB/IEC -approved informed consent. 
If applicable, in cases where the subject's representative(s) gives consent (if allowed according to local requirements), the subject must be informed about the study to the extent possible given his/her understanding. If the subject is capable of doing so, he/she must indicate agreement by [CONTACT_30803]. 
Informed consent must be obtained before conducting any study- specific procedures (e.g. all  of 
the procedures described in the protocol). The process of obtaining informed consent must be 
documented in the subject source documents. 
[COMPANY_001] will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guidelines and regulatory requirements and is considered appropriate for this study. Any changes to the proposed consent form suggested by [CONTACT_6619]/IEC. 
Information about previously known common side effects of the investigational drug can be 
found in the Investigator's Brochure (IB ). This information will be included in the subject 
informed consent and should be discussed with the subject during the study as needed. Any new 
informat ion regarding the safety profile of the investigational drug that is identified between IB 
updates will be communicated as appropriate, for example, via an investigator notification or an aggregate safety finding. New information might require an update to the informed consent 
and then must be discussed with the subject. 
Women of childbearing potential must be informed that taking the study treatment may involve 
unknown risks to the fetus if pregnancy were to occur during the study and agree that, in order to participate in the study , they must adhere to the contraception requirements. 
    
 
Declining to participate i n these optional assessments will in no way affect the subject’s ability 
to participate in the main research study.  
A copy of the approved version of all consent forms must be provided to [COMPANY_001]/sponsor after IRB/IEC approval. 

[COMPANY_001]  Confidential  Page 46  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
8 Visit schedule and assessments  
The assessment schedule ( Table 8 -1) lists all of the assessments and details when they are 
performed. All data obtained from these assessments must be supported in the subject’s source 
documentation. 
Subjects should be seen for all visits on the designated day or as close as possible to the original 
planned visit schedule. Missed or rescheduled visits should not lead to automatic discontinuation.   
During the treatment periods, subjects may be seen at unscheduled visits, e.g., if they experience 
deterioration of lichen planus, or AEs that in the opi[INVESTIGATOR_190212], or repeated laboratory testing. The assess ment(s) performed at an unscheduled visit are at the 
investigator’s discretion. 
In the event of a major health care disruption (e.g., pandemic , epi[INVESTIGATOR_901])  that limits  or prevents 
on site study visits , regular  phone calls (every 4 weeks or more frequently, i f needed) will occur 
until th e subject  can again visit the site.  Events qualifying for being reported in the CRF  (e.g., 
AE, procedure) should be entered as appropriate.   Special effort should be made to collect 
information related to  EOT or End of study visits. If it is not feasible to conduct the EOT  or the 
Week 40  visit on -site, phone calls should be attempted instead . 
Subjects who prematurely discontinue study treatment for any other reason than withdrawal of 
informed consent should not be considered as discontinued from the study, s ee Section 9.1.  
Special effort should be made to ensure that patients who prematurely discontinue study treatment during Treatment Period 1 attend all scheduled visits un til including the Week 
16 visit.  
Assessments should be completed in the following order: 
1. Patient reported outcomes (e.g. DLQI). 
2. Physician reported assessments (e.g. IGA, REU): IGA  should be done first , before 
applying the other physician reported assessments (e.g. REU or LPPAI). 
3. Study visit procedures (e.g. vital signs measurements, laboratory and  
 biopsy procedures). 
 
 

[COMPANY_001]  Confidential  Page 47  
Clinical Trial Protocol Amendment Version 02 ( Clean)  Protocol No. CAIN457S12201  
 
 Table 8-[ADDRESS_410601] 
dose + [ADDRESS_410602] an oral 
affection of the disease.  Demography  X                 
Inclusion / Exclusion criteria  X X               
Smoking history  X                 
Lichen planus medical 
history  X                 
Previous lichen planus 
therapi[INVESTIGATOR_014]  X                 
Other medical history  X                 
Prior medications  X                 
Concomitant medications  update as necessary  
Prior or concomitant non-
drug therapi[INVESTIGATOR_014]/procedures  update as necessary  
Adverse Events  update as necessary  
Vital Signs  X X         X   X X 
Body Height  X                 
Body Weight  X X       X X X X X 
Physical examination  S S               
Hepatitis screen  X                 
Tuberculosis test  S                 
Investigator's Global 
Assessment (IGA)  X X   X   X X X X X 
[COMPANY_001]  Confidential  Page 48  
Clinical Trial Protocol Amendment Version 02 ( Clean)  Protocol No. CAIN457S12201  
 
 Period  Screening  Treatment Period [ADDRESS_410603] 
dose + 4 
weeks  
Physician´s assessment of 
surface area of disease 
(PSAD)3  X   
X   
X X X X X 7 Not to be done if EOT 
already happened  
8 For all patients in the CLP 
cohort.  
9 For all patients in the MLP 
cohort.  
10 Optional  
11 Historical biopsies are 
accepted IF THEY ARE NOT 
OLDER THAN 3 MONTHS 
BEFORE SCREENING VISIT 
and if the investigator is able to 
provide the stained slides to 
the central lab for digitalization . Reticular Erythematous 
Ulcerative (REU) score4   X   X   X X X X X 
Lichen Planopi[INVESTIGATOR_331961] (LPPAI)5   X         X   X X 
Oral Lichen planus symptom 
severity measure (OLPSSM)[ADDRESS_410604] (local)  S S             S7 S 
Pregnancy test (serum)  X                 

[COMPANY_001]  Confidential  Page 49  
Clinical Trial Protocol Amendment Version 02 ( Clean)  Protocol No. CAIN457S12201  
 
 Period  Screening  Treatment Period [ADDRESS_410605] 
dose + [ADDRESS_410606] IRT  S S S7 S7 S7 S7 S7 S7 S7 S 
Drug administration    X X7 X7 X7 X7 X7 X7 X7  
  

[COMPANY_001]  Confidential  Page 50  
Clinical Trial Protocol Amendment Version 02 ( Clean)  Protocol No. CAIN457S12201  
 
 Period  Treatment Period 2  Notes  
Visit Name  [CONTACT_10585] 
17 Week 
18 Week 
19 Week 
20 Week 
22 Week 
24 Week 
26 Week 
28 Week 
30  Week 
32 EOT2  
Visit Numbers1 170 180 190 200 210 220 230 [PHONE_4709]   
Days  [ADDRESS_410607] 
dose + [ADDRESS_410608] a 
concomitant oral affection.  Prior or concomitant non-
drug therapi[INVESTIGATOR_014]/procedures  update as necessary  
Adverse Events2 update as necessary  
Vital Signs            X       X X 
Body Weight        X   X   X   X X 
Physical examination                    S7 S 
Investigator's Global 
Assessment (IGA)        X   X   X   X X 
Physician´s assessment of 
surface area of disease 
(PSAD)3       
X   
X   
X   
X X 
Reticular Erythematous 
Ulcerative (REU) score4       X   X   X   X X 
Lichen Planopi[INVESTIGATOR_331961] (LPPAI)5           X       X X 
Oral Lichen planus symptom 
severity measure (OLPSSM)6       X   X   X   X X 
SCALPDEX5       X   X   X   X X 
DLQI        X   X   X   X X 
Patient assessment of itch        X   X   X   X X 
Patient assessment of pain        X   X   X   X X 

[COMPANY_001]  Confidential  Page 51  
Clinical Trial Protocol Amendment Version 02 ( Clean)  Protocol No. CAIN457S12201  
 
 Period  Treatment Period 2  Notes  
Visit Name  [CONTACT_10585] 
17 Week 
18 Week 
19 Week 
20 Week 
22 Week 
24 Week 
26 Week 
28 Week 
30  Week 
32 EOT2  
Visit Numbers1 170 180 190 200 210 220 230 [PHONE_4709]   
Days  [ADDRESS_410609] 
dose + [ADDRESS_410610] (local)                    S7 S 
Pregnancy test (serum)                       
Skin biopsy8                      
Mucosal biopsy9                      
Scalp biopsy5                   X7 X 
Contact [CONTACT_12067]        S7   S7   S7   S7 S 
Drug administration        X7   X7   X7      
Home administration12 X7 X7 X7   X7   X7   X7    
 
  

[COMPANY_001]  Confidential  Page 52  
Clinical Trial Protocol Amendment Version 02 ( Clean)  Protocol No. CAIN457S12201  
 
 Period  Follow -up  Unplanned  Notes  
Visit Name  [CONTACT_10585] [ADDRESS_410611] an oral affection of the 
disease.  
8 For all patients in the CLP cohort.  
9 For all patients in the MLP cohort.  
13 The assessments performed at an unscheduled visit are at the 
discretion of the investigator  Prior or concomitant non-
drug therapi[INVESTIGATOR_014]/procedures  update as necessary  
Adverse Events  update as necessary  
Vital Signs    X X 
Body Height        
Body Weight    X X 
Physical Examination      S 
Hepatitis screen        
Tuberculosis test      S 
Investigator's Global 
Assessment (IGA)  X X X 
Physician´s assessment of 
surface area of disease 
(PSAD)3 X X X 
Reticular Erythematous 
Ulcerative (REU) score4 X X X 
Lichen Planopi[INVESTIGATOR_331961] (LPPAI)5   X X 
Oral Lichen planus symptom severity measure 
(OLPSSM)6 X X   
SCALPDEX5 X X   
DLQI  X X   
Patient assessment of itch  X X X 
Patient assessment of pain X X X 

[COMPANY_001]  Confidential  Page 53  
Clinical Trial Protocol Amendment Version 02 ( Clean)  Protocol No. CAIN457S12201  
 
 Period  Follow -up  Unplanned  Notes  
Visit Name  [CONTACT_10585] [ADDRESS_410612] (local)      S 
Pregnancy Test (serum)      X 
Skin biopsy8       
Mucosal biopsy9       
Scalp biopsy5       
Contact [CONTACT_332008] 54  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 8.[ADDRESS_410613] number. Patients may also be rescreened at a later time if site closures or 
other logistical issues prevent randomization as planned. Patients presenting with a reduction 
in the IGA score between screening and baseline, with the IGA not qualifying as moderate or severe at the baseline visit (i.e., IGA score of 2, 1 or 0), will not be eligible for re -screening. 
For all rescreened subjects, the investigator/qualified site staff will record if the subject was rescreened on the rescreening eCRF and the original screening number the subject was issued prior to the current screening number. 
Informed Consent for a rescreened subject must be obtained prior to performing any study-
related assessment or collecting any data for the Screening Visit. For rescreening, all screening assessments must be performed as per protocol, except for the tuberculosis (TB) work up, if applicable, if perf ormed not more than [ADDRESS_410614] repeat the QuantiFERON -TB Gold assay performed by [CONTACT_2237]. 
Information to be collected on screening failures  
Subjects who sign an informed consent form and subsequently found to be ineligible prior to randomization will be considered a screen failure. The reason for screen failure should be recorded on the appropriate CRF . The demographic information, informed consent, and 
Inclusion/Exclusion pages must also be completed for screen failure subjects. No other data will be entered into the clinical database for subjects who are screen failures, unless the subject experienced a serious adverse event during the screening phase ( Section  10.1.3, SAE reporting). 
Adverse events that are not SAEs will be followed up by [CONTACT_90200]. If the subject fails to be randomized, the IRT must be notified within [ADDRESS_410615] demographics/other baseline characteristics  
Country- specific regulations should be considered for the collection of demographic and 
baseline characteristics in alignment with the CRF.  
8.2.1  Demography  
Subjects demographics data will include: age, gender, race and ethnicity. 
8.2.2  Prior Lichen Planus medical history and previous therapi[INVESTIGATOR_331962]: 
• lichen planus subtype: Cutaneous lichen planus, mucosal lichen planus, lichen 
planopi[INVESTIGATOR_22785] (note that the predominant subtype as well as potential concurrent subtypes, if present, are collected) .   
• date of first symptoms  
• date of first diagnosis of lichen planus 
[COMPANY_001]  Confidential  Page 55  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 • any treatments for lichen planus since initial diagnosis prior to study entry will be 
collected and recorded in the eCRF along with the duration of the prior therapy and reason for discontinuation. 
8.2.3  Smoking history  
The current and/or previous tobacco use will be recorded prior to randomization, as well as the estimated number of pack -years based on the approximate consumption per year. Use of e -
cigarettes will be recorded in the Medical history CRF. 
8.2.4  Medical history/current medical conditions 
Relevant medical history and current medical conditions includes data prior to signing of the 
informed consent and should be recorded in the Medical History eCRF. Whenever possible, diagnoses and not symptoms should be recorded. 
Significant findings that are observed after the subject has signed the ICF and that meet the 
definition of an AE must be recorded in the AE eCRF.  
8.2.5  Prior and concomitant medications  
Concomitant medications and prior medications taken over the 6 months preceding study enrollment for reasons other than lichen planus will be captured at the screening visit, and updated as necessary in the relevant eCRF.  
8.2.6  Determination of the tuberculosis  status  
Determination of tuberculosis (TB) status should be done at Screening and should be performed as defined by [CONTACT_13144]. The TB status must be determined by [CONTACT_9870], signs, symptoms, and TB testing (QuantiFERON -TB Gold assay). Any significant findings should be 
recorded in the eCRF   (Section 15.3) for more details.  
8.3 Efficacy 
The following section describes the efficacy measures applied in this study. Whenever possible 
the following assessments should be performed by [CONTACT_332009]. 
8.3.1  Investigator’s Global Assessment (IGA)  
The IGA grading should be done first,  before performing any other physician assessments 
(e.g. REU, LPPAI, etc). Whenever possible, the IGA assessment should be performed by [CONTACT_332010]. 
The IGA  table ( Table 8-2 ) will provide a harmonized, 5- point grading system to assess disease 
severity for patients of all 3 subtypes entering the study. The predominant subtype defines the IGA score of the patient.   
The IGA grading is based on the predominant subtype alone, meaning on the subtype of 
the cohort the patient is in. In addition, the IGA score is also collected separately  for 
concomitant subtypes, if present.  
  
[COMPANY_001]  Confidential  Page 56  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 Table 8-2 Investigator's Global Assessment grading  
IGA score  Cutaneous Lichen 
Planus  Mucosal Lichen 
Planus  Lichen Planopi[INVESTIGATOR_22785]  
[ADDRESS_410616] negative.  
1 - Minimal  Barely palpable (<0.5 
mm), scattered 
papules, mild 
erythema.  
Typi[INVESTIGATOR_331963].  Reticular, white, patch-
type striations 
involving any oral or 
genital mucosal site(s) (“Wickham Striae”). Absence of ulcers.  
Typi[INVESTIGATOR_331964].  Predominantly  inactive 
disease 
(hypopi[INVESTIGATOR_331965]). Absence of disease spreading. Pull test negative. Minimal scalp erythema and/or 
perifollicular erythema 
without scale.  
Typi[INVESTIGATOR_331966].  
2 - Mild Moderately elevated papules (<1 mm) and/or small plaques (<2 cm
2). Involvement 
of limited areas, erythema.  
Typi[INVESTIGATOR_331967].  Plaque -type, mucosal 
lichen planus involving any oral or genital mucosal site(s). 
Absence of ulcers  or 
presence of one focal 
ulceration (<0.5 cm
2). 
Typi[INVESTIGATOR_331968].  Rare perifollicular 
erythema, rare perifollicular hyperkeratosis and 
interfollicular scale. 
Stable or slowly spreading disease. Pull test negative.  
Typi[INVESTIGATOR_331969].  
3 - Moderate  Thick, elevated (<2 mm), hypertrophic, violaceous papules or presence of non-hypertrophic, plaque-like disease (>2 cm
2), 
either generalized or 
involving specific 
areas or specific locations (e.g. face, neck). Red/violaceous erythema, possible scales.  
Typi[INVESTIGATOR_331970].  Desquamative gingivitis or vulvitis. Presence of unilateral or bilateral ulcer ation s 
involving any oral or genital mucosal site(s). Overall area affected 
by [CONTACT_332011] <[ADDRESS_410617] 
positive for telogen hairs.  
Typi[INVESTIGATOR_331970], 
pain and/or burning.  
[COMPANY_001]  Confidential  Page 57  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 4 - Severe  Generalized, papular 
or plaque- type, 
elevated lesions (>2 
mm) OR localized 
hypertrophic lesions (>2 cm
2). Marked 
red/violaceous erythema. Possible 
scales, blisters and 
ulcers.  
Typi[INVESTIGATOR_331971].  Presence of bilateral 
or extensive unilateral 
ulcers involving any 
oral or genital mucosal site(s). Overall area 
affected by [CONTACT_332012] >2 cm
2. 
Possible esophageal 
involvement 
(established by [CONTACT_235127]).  
Typi[INVESTIGATOR_331972] s evere pain and 
sensitivity.  Hairless patches with 
perifollicular and 
interfollicular, intense 
erythema, extensive perifollicular and interfollicular scaling. Crusting, pustules. Active spreading 
disease. Pull test 
positive for telogen or anagen hairs.  
Typi[INVESTIGATOR_331973], 
pain and/or burning.  
The grading should be mainly driven by [CONTACT_332013].  Symptoms, such as pain 
or pruritus, may or may not be associated. 
8.3.2  Physician´s assessment of surface area of disease ( PSAD)  
The Physician Assessment of Surface Area of Disease (PSAD) evaluates the extent of cutaneous 
lesions. Since no validated scales are available to quantify the area of disease in CLP, the present study will utilize the PSAD grading score as previously reported in the only randomized trial conducted with a biologic therapy in CLP (etanercept, [STUDY_ID_REMOVED]). 
The PSAD will be estimated by [CONTACT_093]/trained qualified designee from the percentages 
of areas affected, including head, trunk, upper limbs and lower limbs. Whenever possible, the same assessor should perform the PSAD assessment at all visits. The assessor will report the percentage of the surface area involved with disease using a Likert scale.   
Assessment scores range from 0 -5, with lower scores corresponding to lower percentages of 
surface area with disease.  
0: clear  
1: <2% of the total body surface area.  Small, localized papules 
2: 2-9% of the total body surface area.  Lesions affecting limited areas (e.g. wrists or ankles)  
3: 10-29% of the t otal body surface area.  Lesions affecting extensive areas (e.g. upper limbs or 
back ) 
4: 30-50% of the total body surface area. Lesions affecting extensive areas or in multiple 
locations (e.g. trunk and lower/upper limbs) 
5: >50% of the total body surface a rea. Generalized involvement  
As reference, the percentages utilized for the Body Surface Area (BSA)  assessment should be 
considered (head=10%, trunk=30%, upper limbs=20%, lower limbs=40%). Post-inflammatory hyperpi[INVESTIGATOR_331974].  
[COMPANY_001]  Confidential  Page 58  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 The PSAD assessment is required for all subjects enrolled in the CLP cohort. In addition, the 
PSAD assessment is required for subjects enrolled in the MLP cohort in case they have a concomitant  cutaneous involvement. 
8.3.3  Reticulations, erythema and ulcerations (REU) score  
The reticulation, erythema and ulcerations score (REU score) was developed by [CONTACT_25715][INVESTIGATOR_331975]. as a semiquantitative scale for the assessment and monitoring of oral lichen planus as well as oral graft -versus -host disease ( Pi[INVESTIGATOR_331976] 2005). It measures disease severity based 
on 3 dimensions: reticulation, erythema and ulceration. Whenever possible, the REU assessment should be performed by [CONTACT_332009]. 
The REU score is app lied for all patients in the MLP cohort who have an oral  presentation of 
the disease. In addition, the REU scoring is also done for patients in the CLP cohort in case they 
have a concomitant oral  involvement. 
The assessment is done as follows: 
The oral cav ity is divided into the following 10 sites: 
• upper/lower labial mucosa 
• right buccal mucosa 
• left buccal mucosa  
• dorsal tongue 
• ventral tongue 
• floor of mouth 
• hard palate mucosa  
• soft palate/tonsillar pi[INVESTIGATOR_36523]  
• maxillary gingiva 
• mandibular gingiva 
The severity of the lesions is scored for each site individually according to the presence of 
reticular/hyperkeratotic, erosive/erythematous and ulcerative lesions: 
• Reticulation: reticular/hyperkeratotic lesions: 0 - 1  
• 0: no white striations  
• 1: presence of white striation s or keratotic papules 
• Erythema: erosive/erythematous lesions by [CONTACT_332014]: 0 - 3  
• 0: no lesion 
• 1: lesions < 1 cm
2 
• 2: lesions 1 - 3 cm2 
• 3: lesions > 3 cm2 
• Ulceration: ulcerative lesions by [CONTACT_332014]: 0-3  
• 0: no lesion 
• 1: lesions < 1 cm2 
• 2: lesions 1 - 3 cm2 
[COMPANY_001]  Confidential  Page 59  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 • 3: lesions > 3 cm2 
For each of the 3 clinical dimensions, a score is then derived by [CONTACT_332015] 10 oral cavity sites: Reticular score = ∑R, erythema score = ∑E, and ulcerative score = ∑U.  
These 3 scores then add up to a total weighted score: ∑R + ∑(E x 1.5) + ∑(U x 2.0).  
8.3.4  Lichen planopi[INVESTIGATOR_331977] (LPPAI)  
The LPPAI is a numeric score to quantify the signs and symptoms of LPP introduced by [CONTACT_332016]. ( Chiang et  al 2010 ). The LPPAI assesses symptoms (pruritus, pain, burning), signs 
(erythema, perifollicular erythema and scale), a measure of activity (pull test) and extension of disease. These subjective and objective measures are assigned numeric values to establish a disease activity score. Whenever possible, the LPPAI assessment should be performed by [CONTACT_332009]. It is applied for subjects in the LPP cohort only. 
Table 8-[ADDRESS_410618]  0 / 1 & anagen / total  
Spreading  0 - 2 
Score for signs and symptoms: 0=absent, 1=mild, 2=moderate, 3=severe  
Score for anagen pull test: To conduct the anagen pull test grasp a small group of [ADDRESS_410619] from the scalp with a slow, firm perpendicular force to slide the fingers to the ends of the hair. The result is recorded both as a binary value ( 0 for no anagen h airs, 1 for the presence of anagen 
hairs) and as anagen hairs/total hairs pulled. 
Score for spreading: 0 = no spreading, 1 = indeterminate, 2 = spreading. When the hair loss is 
difficult to judge, the issue of spreading is recorded as indeterminate. 
The weights given to the symptoms (30%), signs (30%), anagen pull test (25%) and presence 
of spreading (15%) then lead to the final equation: 
LPPAI (0 -10) = (pruritus + pain + burning + scalp erythema + perifollicular erythema + 
perifollicular scale)/3 + 2.5x(pull test) + 1.5x(spreading/2)  
8.3.5  Appropriateness of efficacy assessments  
IGA: Using an IGA type of assessment represents the most widely used assessment strategy to 
evaluate patients' disease severity and improvement. It has been utilized as a primary endpoint 
in several clinical trials investigating psoriasis, and it is routinely used in clinical practice. 
[COMPANY_001]  Confidential  Page 60  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 Available IGA  scores are not adequate to assess disease severity in lichen planus, nor to 
describe the complex features of lichen planus. The IGA presented in this study has been 
developed with the contribution of the medical experts included in the Steering Committee, and describes the different stages of disease severity harmonizing the scores across the different subtypes of lichen planus. This represents the first attempt to develop a unified dermatologic score to assess disease severity in patients with lichen planus. 
PSAD: the PSAD is a quantitative score describing the extent of the disease in patients with 
lichen planus. It is not a validated score: in fact, the paucity of RCTs conducted in patients with 
CLP led to the absence of standardized measurements to assess the severity of the disease. The only RCT conducted with a biologic therapy in this population (etanercept, [STUDY_ID_REMOVED]) utilized th is scale: as the disease localization can be different from other skin diseases (i.e. 
psoriasis), BSA may not be the preferred measurement. This study will elucidate the role of PSAD in the assessment of disease severity in lichen planus.  
LPPAI: the LPPAI is a numeric score to quantify the signs and symptoms of LPP introduced 
by [CONTACT_332016]. ( Chiang et al 2010). It is the only available disease -specific score for LPP and 
was used in a number of trials/case series to measure treatment efficacy in this indication (Naeini  et al 2017; Fonda- Pascual  et al 2018; Yang  et al 2018) 
REU: the reticulations, erythema and ul cerations score (REU score) was developed by 
[CONTACT_25715][INVESTIGATOR_331975]. as a semiquantitative scale for the assessment and monitoring of oral lichen planus as well as oral graft -versus- host disease ( Pi[INVESTIGATOR_331976] 2005). It measures disease 
severity based on reticulations, erythema and ulceration. It is easy to use, offers a high intra as 
well as inter -observer reliability ( Pi[INVESTIGATOR_331976] 2005; Gobbo et  al 2017), correlates with 
pain and reliably reflects improvement attributable to treatment ( Park et al 2012).  
8.4 Safety/Tolerability 
All blood draws and safety assessments should be done prior to study treatment admini stration. 
Appropriate safety assessments (e.g., evaluation of AEs and SAEs) should be repeated after the dose is administered. 
Safety assessments are specified below with the assessment schedule detailing when each 
assessment is to be performed.   
In the event of a major health care disruption (e.g., pandemic, epi[INVESTIGATOR_901] ) that limits or prevents 
on-site study visits, regular phone will occur (every 4 weeks or more frequently if needed)  for 
safety monitoring and discussion of the patient´s  health status until the patient can again visit 
the site. E vents qualifying for being reported in the CRF  (e.g., AE, procedure) should be entered 
as appropriate.  If patients cannot visit the site to ha ve urine pregnancy tests done, the urine 
pregnancy test kits can be provided to the patient or shipped directly to the patient’s home  (e.g., 
together with the study drug). After appropriate instruction, patients can perform the urine pregnancy test at home  and report the result to the site. It is important that patients do the 
pregnancy test first and only if the test result is negative proceed with the administration of the study drug.  
For details on AE collection and reporting, refer to Section  10.1.1. 
[COMPANY_001]  Confidential  Page 61  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 Table 8-4 Assessments &  Specifications  
Assessment  Specification  
Physical examination  A physical examination, including general 
appearance, skin, neck, eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, extremities, vascular and neurological systems will be performed as indicated in Table  8-1. 
If necessary, based on medical history and/or symptoms, additional exams will be performed at the discretion of the investigator.  
Whenever possible, assessments for an 
individual subject should be performed by [CONTACT_37260].  
Information for all physical examinations must be included in the source documentation at the study site. Clinically relevant findings that are present prior to signing informed consent must be recorded on the appropriate CRF that 
captures medical history. Significant findings 
made after signing informed consent which meet the definition of an Adverse Event must be 
recorded as an adverse event.  
Vital signs  Vital signs (including blood pressure and pulse 
measurements) will be assessed as indicated in 
Table  8-1. Whenever possible, assessments 
should be performed by [CONTACT_332017].  
After the subject has been sitting for five 
minutes, with back supported and both feet 
placed on the floor, systolic and diastolic blood 
pressure will be measured twice (measurements separated by 1 to 2 minutes) using an appropriate device, with a correctly sized cuff (Mancia  2007
). In case the cuff sizes available 
are not large enough for the subject’s arm 
circumference, a sphygmomanometer with an 
appropriately sized cuff may be used. Measurements will be recorded in the source documentation and the average of the two measurements will be entered on the Vital Signs 
eCRF section.   
[COMPANY_001]  Confidential  Page 62  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 Normal blood pressure will be defined as a 
systolic pressure of 90 to < 120mmHg, and a diastolic blood pressure of 60 to < 80 mmHg under measurement conditions as outlined above. Notable blood pressure will be hypertension (systolic ≥ 140 mmHg and/or 
diastolic > 90 mmHg) or hypotension (systolic < 
90 mmHg and/or diastolic < 60 mmHg). A blood pressure indicative of pre- hypertension (systolic 
120 to < 140 mmHg and/or diastolic 80 to < 90 mmHg) will not be regarded as notable (Chobanian et  al 2003).  
A normal pulse rate will be defined as a rate of 60 to 100 bpm (beats per minute) under the measurement conditions outlined above. Notable pulse rates are a rate below 60 bpm (bradycardia) or above 100 bpm (tachycardia).  
No specific action is pre- defined within this 
protocol to respond to specific abnormal vital signs, as it will be decided by [CONTACT_332018], taking 
into account the overall status of the sub ject. 
Height and weight  Height and body weight will be measured as listed in Table  8-1. 
Height and body weight will be measured in indoor clothing, but without shoes. Whenever, possible, body weight assessments should be performed by [CONTACT_332019]; 
the same scale should be used throughout the 
study.  
8.4.1  Laboratory evaluations  
A central laboratory will be used for analysis of all specimens listed below, unless noted 
otherwise. Details on the collections, shipment  of samples and reporting of results by [CONTACT_332020]. Refer to the Laboratory Manual for identification of laboratory reference range values and the schema for notification of site staff and [COMPANY_001] for out of range values. 
Subjects should avoid smoking within the hour preceding the blood draws. Appendix 1 (Section  15.1) shows the extended laboratory ranges that are considered clinically notable. No 
specific action is pre -defined within this protocol to respond to specific abnormal laboratory 
values, as it will be decided by [CONTACT_332018], taking into account the overall status of the subject. 
The tests will be conducted as defined in the assessment schedule.  
Test Category  Test Name  
[CONTACT_6675], Hemoglobin, Platelets, Red blood 
cells, White blood cells, Differential (Basophils, Eosinophils, Lymphocytes, Monocytes, 
Neutrophils)  
[COMPANY_001]  Confidential  Page 63  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 Chemistry  Albumin, Alkaline phosphatase, ALT, AST , 
Gamma- Glutamyl -Transferase (GGT), Lactate 
Dehydrogenase (LDH), Bicarbonate, Calcium, Magnesium, Phosphorus, Chloride, Sodium, Potassium, Creatinine, Total Bilirubin, Total Cholest erol, LDL, HDL, Total Protein, 
Triglycerides, Urea, Uric Acid, HbA1c, hs -CRP 
(will not be communicated to the site staff, incl. the investigator, or to [COMPANY_001] during the study 
to maintain blinding)  
Hepatitis Screening  Hepatitis screening will be conducted at the 
screening visit.  
Pregnancy Test  Serum / Urine pregnancy test  
8.4.[ADDRESS_410620] not be given to pregnant women; therefore, effective methods of 
birth control must be used for women of childbearing potential (see exclusion criteria definitions, Section  5.2).  
A serum Human Chorionic Gonadotropin ( β-hCG) test will be performed at Screen ing in all 
women of childbearing potential. In addition, local urine pregnancy test s must be performed as 
indicated in Table [ADDRESS_410621] be discontinued from the study treatment (see Section 9.1). 
Additional pregnancy testing may be performed as per local requirements. 
8.4.[ADDRESS_410622] measures for clinical trials with a biologic, 
immunomodulating agent in dermatologic diseases. 
8.5 Additional assessments 
The following additional assessments will be applied in this trial: 
• Patient Reported Outcomes (PROs)  
  
  
•   
  
  
  

[COMPANY_001]  Confidential  Page 64  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 8.5.1  Patient Reported Outcomes (PROs)  
The following PROs will be applied as specified in Table 8-1: 
  
  
• Patient Assessment of Itch  (NRS) 
• Patient Assessment of Pain  (NRS) 
• Oral Lichen Planus Symptom Severity Measure (OLPSSM) 
• Dermatology Life Quality Index (DLQI) 
  
• SCALPDEX 
All questionnaires will be completed in the language the respondent  is most familiar with, at 
the scheduled visit before the subject sees the investigator for clinical assessments. The subject 
should be given sufficient space and time to complete the questionnaires. Oral Lichen Planus Symptom Severity Measure (OLPSSM):  
The Oral Lichen Planus Symptom Severity Measure (OLPSSM) was developed by [CONTACT_332021]. 
as a PRO -based assessment of the symptom experience of subjects with oral lichen planus 
(Burke et  al 2019) in clinical studies.  
It includes 7 triggers contributing to soreness of oral lichen planus: Brushing teeth, eating food, 
drinking liquids, smiling, breathing through mouth, talking and touching. These [ADDRESS_410623] an oral affection of the 
disease.  
Dermatology Life Quality Index:  
The DLQI is a 10 -item general dermatology disability index designed to ass ess health -related 
quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, 
and viral warts ( Finlay  and Khan  1994). The measure is self -administered and includes domains 
of daily act ivities, leisure, personal relationships, symptoms and feelings, treatment, and 
work/school. The measure is widely used: it has been tested across [ADDRESS_410624] week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). “Not relevant” is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment. Each subscale of the DLQI may also be analyzed separately.  
The DLQI is given to all subjects in the study. 
Scalpdex:  
Scalpdex is a self -administered, health -related quality of life ins trument originally developed 
for scalp dermatitis. This 23- item survey evaluates the subject across three major domains – 
symptom, functional, and emotion ( Chen  2002). Subjects will be asked to score themselves on 
how t rue each of the [ADDRESS_410625] four weeks. The items are 

[COMPANY_001]  Confidential  Page 65  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 scored on a scale of 0 -100, where 0=never, 25=rarely, 50=sometimes, 75=often and 100=all the 
time.   
The Scalpdex is given to subjects in the LPP cohort only. 
Patient Assessment of Itch:  
Itch is assessed with the following questions: 
• "Overall, how severe was your lichen planus-related itching during the past 24 hours?" 
• "How severe was your  lichen planus- related itching at the worst moment  during the past 
24 hours?" 
• "Overall, how bothered were you by [CONTACT_332022]-related itching during the past 24 
hours?" 
Answers are given on a numeric rating scale (NRS). The Patien t Assessment of Itch is done by 
[CONTACT_35668] . 
Patient Assessment of Pain:  
Pain is assessed with the following questions: 

[COMPANY_001]  Confidential  Page 66  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 • "Overall, how severe was your lichen planus-related pain during the past 24 hours?" 
• "How severe was your  lichen planus- related pain at the worst moment  during the past 24 
hours?" 
• "Overall, how bothered were you by [CONTACT_332022]-related pain during the past 24 
hours?" 
Answers are given on a numeric rating scale (NRS). The Patient Assessment of Pain is done by [CONTACT_35668].  

[COMPANY_001]  Confidential  Page 67  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 8.5.
4 B iomarkers  
Tissue biomarkers: Biopsies  
Punch biopsies will be taken at the visits defined in the assessment schedule ( Table 8-1) and 
sent to the  central laboratory  or to a local pathologist. Detailed instructions on the biopsy 
procedure, sample harvesting, preparation, storage and shipment are provided in the laboratory 
manual.  
The initial biopsies will be taken at the Screening visit, after the urine  pregnancy test has shown 
a negative result for women of childbearing potential . They will be used to obtain a histological 
confirmation of the diagnosis of lichen planus. The histological confirmation of the diagnosis is mandatory and an inclusion criterion of this study. It is allowed to leave out the biopsy at Screening visit and use a historical biopsy, if available, instead. However , this is only allowed 
in case the historical biopsy has not been taken longer than 3 months prior to Screening visit and the stained histology slides are available and can be shared with the ce ntral laboratory for 
digitalization .     
 

[COMPANY_001]  Confidential  Page 68  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 In case the (screening ) biopsies have been assessed by a local pathologist, 
sta
ined histology slides should be sent to the central laboratory for digitalization. Appropriate 
slides representative of the current morphological characteristics and activity of the disease 
should be selected . 

[COMPANY_001]  Confidential  Page 69  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 8.5.5  Other Assessments  
PRO feedback assessment (optional and only applicable for patients/ sites in 
the [LOCATION_003])  
Using qualitative, semi- structured, open ended questions, feedback from a selected number of 
trial patients might be asked in optional exit interviews for their experienc e with the Patient -
Reported Outcome measures to inform the future lichen planus clinical trial program. 
[ADDRESS_410626] occurs when the  study treatment is stopped 
earlier than the protocol planned duration (i.e., < Week 32) and can be initiated by [CONTACT_332023]. 
The investigator must discontinue study treatment for a given subject if he/she believes that 
continuat ion would negatively impact the subject's well -being. Prior to discontinuation this 
should be discussed with and communicated to the sponsor's medical expert.  
Study treatment must be discontinued under the following circumstances: 
• Subject decision  
• Withdrawal of consent 
• Pregnancy  
• A patient on placebo treatment in Treatment Period 1 achieves spontaneous remission 
(defined by [CONTACT_332024] 0 or 1) at the Week 16 visit 
• Ongoing use of prohibited treatment, use of a prohibited treatment that results in an undue safety risk for the subject as per the investigator’s clinical judgment, or receipt of a live virus vaccine during the study (as detailed in Section  6.2.2) 
• Any protocol deviation in which study participation might result in a safety risk to the subject  
• Emergency unblinding 
• AEs that in the judgment of the investigator/qualified site staff, taking into account the patient’s overall status prevent the subject from continuing study treatment 
• Any laboratory abnormalities that in the judgment of the investigator, taking into consideration the patient’s overall status, prevents the subject from continuing participation in the study 
If discontinuation of study treatment is due to the subject, the investigator should make a reasonable effort to understand the primary reason for the subject’s premature discontinuation 
of study treatment and to record this information. 
Subjects who discontinue study treatment should NOT be considered withdrawn from the study 
UNLESS they withdraw their consent (see Section 9.1.3 'Withdrawal of Informed Consent'). 
[COMPANY_001]  Confidential  Page 70  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 Subjects should continue attending planned s ite visits and perform the study assessments  until 
the last visit of the study period during which they discontinue (Week 16 or Week 32).  
• Subject s, whether they are willing to continue attending further study visits  or not , 
should attend an End of Treatm ent (EOT) visit of the  study period during which they 
discontinued (EOT 1 for discontinuation during Treatment Period 1 and EOT 2 for 
discontinuation during Treatment Period 2) . The scheduled visit that was  planned to take 
place will then not be performed and will be replaced by [CONTACT_197295]. 
•  Subjects who are willing to continue will attend visits until Week 16 or Week 32 
according to the schedule and will then move to the Follow-up period. 
• Subjects who are unwilling to continue attending study visits wil l move directly to the 
Follow up period after their EOT visit 
• Subjects who discontinue study at the same time as study treatment will end their 
participation after their EOT visit (see also  Section 9.1.2).  
The investigator must also contact [CONTACT_37284]’s discontinuation from study treatment.  
If discontinuation occurs because treatment code has been broken, please refer to section 6.6.3.  
If the subject fails to return for EOT assessments for unknown reasons, every effort (e.g. 
telephone, e -mail, letter) should be made to contact [CONTACT_423]/pre -designated contact [CONTACT_332025] -up section. This contact [CONTACT_332026]. 
9.1.[ADDRESS_410627] discontinues study during a treatment period, EOT visit should be performed (see 
Section 9.1.1 above). If a subject discontinues study during Follow up period, visit Week [ADDRESS_410628] cannot or is unwilling to attend any visit(s)  after EOT , the site staff should 
maintain regular telephone contact [CONTACT_1155], or with a  person pre -designated by [CONTACT_1560]. This telephone contact [CONTACT_6636]. Documentation of attempts to contact [CONTACT_332027]. 
9.1.[ADDRESS_410629]: 
• Does not want to participate in the study anymore 
• Does not allow further collection of personal data 
• Does not want any further study related contacts 
• Does not allow analysis of already obtained biologic material 
[COMPANY_001]  Confidential  Page 71  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information. 
Study treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing. 
Further atte mpts to contact [CONTACT_109032]-up. All efforts should be made to complete the assessments prior to study withdrawal. A final 
evaluation at the time of the subject’s study withdrawal should be made as detailed in the 
assessment table.  
[COMPANY_001] will continue to keep and use collected study information (including any data resulting from the analysis of a subject’s samples until the time of withdrawal) according to applicable law. 
For US: all biological samples not yet analyzed at the time of withdrawal may still be used for further testing/analysis in accordance with the terms of this protocol and of the informed consent form.  
For EU and RoW: all biological samples not yet analyzed at the time of withdrawal will no longer be used, unless permitted by [CONTACT_1289]. They will be stored according to applicable legal requirements.  
9.1.[ADDRESS_410630] show "due diligence" by 
[CONTACT_762], e.g. dates of telephone calls, registered letters, etc. A subject should not be considered as lost to follow -up until due 
diligence has been completed or until the end of the study has occurred. 
9.1.5  Early study termination by [CONTACT_201078]. This may include reasons 
related to the benefit/ risk  assessment of participating in the study, practical reasons (including 
slow enrollment), or for regulatory or medical reasons. In taking the decision to terminate, [COMPANY_001] will always consider the subject welfare and safety. Should early termination be necessary, subjects must be seen as soon as possible (and be provided instruction on when the subject should stop self administrating the drug, when the subject should come for a final visit) and treated as a prematurely withdrawn subject. The investigator may be informed of additional procedures to be followed in order to ensure that adequate consideration is given to the protection of the subject’s interests. The investigator or sponsor depending on the local regulation will be responsible for informing IR Bs/IECs of the early termination of the trial.  
9.[ADDRESS_410631] finishes their Study Completion visit  
(Week 40) , and any repeat assessments associated with this visit have been documented and 
[COMPANY_001]  Confidential  Page 72  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 followed- up appropriately by [CONTACT_737], or in the event of an early study termination 
decision, the date of that decision. 
A subject will be considered to have completed the study if he/she received a maximum of [ADDRESS_410632] 
refer them for appropriate ongoing care. 
10 Safety moni toring and reporting 
10.1 Definition of adverse events and reporting requirements 
10.1.1  Adverse events  
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and 
unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. 
In addition, all reports of intentional misuse and abuse of the product are also considered an 
adverse event irrespective of whether a clinical event has occurred.  
The investigator has the responsibility for managing the safety of individual subject and identifying adve rse events.  
[COMPANY_001] qualified medical personnel will be readily available to advise on trial related medical questions or problems. 
The occurrence of adverse events must be sought by [CONTACT_105]- directive questioning of the subject at 
each visit during the study. Adverse events also may be detected when they are volunteered by 
[CONTACT_109049], laboratory test findings, or other assessments. 
Adverse events must be recorded in the Adverse Events eCRF under the signs, symptoms or 
diagnosis associated with them, accompanied by [CONTACT_6644] (as far as possible) (if the event is serious refer to Section  10.1.2):  
1. The severity grade. 
• mild: usually transient in nature and generally not interfering with normal activities  
• moderate: sufficiently discomforting to interfere with normal activities  
• severe: prevents normal activities  
2. Its relationship to the study treatment (suspected: Yes/No). If the event is due to lack of 
efficacy or progression of underlying illness (i.e. progression of the study indication), the assessment of causality will usually be ‘Not suspected’. The rationale for this guidance is that the symptoms of a lack of efficacy or progression of underlying illness are not caused by [CONTACT_6645], they happen in spi[INVESTIGATOR_6532]/or both lack of efficacy and progression 
[COMPANY_001]  Confidential  Page 73  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 of underlying disease can only be evaluated meaningfully by [CONTACT_6646], not on a 
single subject. 
3. Its duration (start and end dates) or if the event is ongoing, an outcome of not recovered/not 
resolved must be reported. 
4. Whether it constitutes a serious adverse event (SAE - see Section  10.1.2 for definition of 
SAE) and which seriousness criteria have been met.  
5. Action taken regarding with study treatment. All adverse events must be treated appropriately. Treatment may include one or more of the 
following: 
• dose not changed 
• dose reduced/increased  
• drug interrupted/withdrawn  
6. Concomitant medication or non-drug therapy given 
7. Its outcome: not recovered/not resolved, recovered/resolved, recovered/resolved with 
sequelae, fatal, unknown 
Conditions that were already present at the time of informed consent should be r ecorded in 
medical history of the subject.  
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis whenever possible, rather than individual underlying signs and symptoms. 
Adverse event monitoring should be continued for at least [ADDRESS_410633] be followed until its resolution or until it is judged to be permanent (e.g. Continuing at the end of the study), and assessment must be ma de at each 
visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to the interventions required to treat it, and the outcome. 
Worsening of lichen planus  in this study is evaluated via the use of efficacy assessments  (e.g. 
IGA, REU, LPPAI, PSAD) and is not  expected to be captured as an AE in the CRF capturing 
adverse events. Exceptions include cases when a new type of lichen planus is diagnosed, or the 
worsening is so severe that a qualitatively different status is re ached.  
Information about adverse drug reactions for the investigational drug can be found in the Investigator's Brochure (IB). 
Abnormal laboratory values or test results constitute adverse events only if they fulfill at least 
one of the following criteria: 
• they induce clinical signs or symptoms 
• they are considered clinically significant  
• they require therapy  
Clinically significant abnormal laboratory values or test results must be identified through a 
review of values outside of normal ranges/clinically notable ranges, significant changes from baseline or the previous visit, or values, which are considered non- typi[INVESTIGATOR_331978] 74  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 underlying disease. Alert ranges for laboratory and other test abnormalities are included in 
Section  15.1. 
10.1.2  Serious adverse events 
An SAE is defined as any adverse event [appearance of (or worsening of any pre -existing)] 
undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following criteria:  
• fatal 
• life-threatening  
Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically might have caused death if it were more severe (please refer to the ICH -E2D Guidelines). 
• results in persistent or significant disability/incapacity  
• constitutes a congenital anomaly/birth defect 
• requires inpatient hospi[INVESTIGATOR_1081], unless hospi[INVESTIGATOR_062]:  
• routine treatment or monitoring of the studied indication, not associated with any deterioration in condition 
• elective or pre- planned treatment for a pre -existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent 
• social reasons and respi[INVESTIGATOR_108999]’s general condition 
• treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063]  
• is medically significant, e.g. defined as an event that jeopardizes the subject or may require medical or surgical intervention to prevent one of the outcomes listed above 
Medical and scientific judgment should be exercised in deciding whether other situations should be considered serious reactions, such as important medical events that might not be immediately life threatening or result in death or hospi[INVESTIGATOR_331979]. Such events should be considered as “medically significant.” Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias, or convulsions that do not result in hospi[INVESTIGATOR_6536]  (please refer to the ICH -
E2D Guidelines). 
All malignant neoplasms will be assessed as serious under “medically significant” if other 
seriousness criteria are not met and the malignant neoplasm is not a disease progression of the study indication. 
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.  
All reports of intentional misuse and abuse of the product are also considered serious adverse event irrespective if a clinical event has occurred.  
[COMPANY_001]  Confidential  Page 75  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 10.1.[ADDRESS_410634] has 
provided informed consent and until 30 days [after the last study visit  (Week 40)  must be 
reported to [COMPANY_001]  safety within 24 hours of learning of its occurrence. Detailed instructions 
regarding the submission process and requirements are to be found in the investigator folder provided to each site. 
1. Screen Failures  (e.g. a subject who is screened but is not treated or randomized): SAEs 
occurring after the subject has provided informed consent until the time the subject is 
deemed a Screen Failure must be reported to [COMPANY_001]. 
2. Randomized OR Treated Subjects : SAEs collected bet ween time subject signs ICF until 
[ADDRESS_410635] be reported separately  as a new event.  
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new occurrence) and is thought to be related to the study treatment, a CMO & PS Department associate may urgently require further information from the investigator for health authority reporting. [COMPANY_001]  may need to issue an Investigator Notification (IN) to inform all 
investigators involved in any study with the same study treatment that this SAE has been reported. 
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 2011/C 172/[ADDRESS_410636] be reported to [COMPANY_001] / within 24 hours of learning of its occurrence. The pregnancy should be 
followed up to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. 
Pregnancy should be recorded and reported by [CONTACT_332028] (CMO&PS). Pregnancy follow -up should be recorded on the same 
[COMPANY_001]  Confidential  Page 76  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
form and should include an assessment of the possible relationship to the study treatment  any 
pregnancy outcome. Any SAE experienced during pregnancy must be reported. 
10.1.5  Reporting of study treatment errors including misuse/abuse  
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, subject or consumer (EMA definition). 
Misuse refers to situations where the medicinal product is intentionally and inappropriately used  
not in accordance with the protocol. Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by [CONTACT_3584]. 
Study treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate CRF irrespective of whether or not associated with an AE/SAE and reported to Safety only if associated with an SAE. Misuse or abuse will be collected and reported in the safety database irrespecti ve of it being associated with an AE/SAE within 24 hours of 
Investigator’s awareness.  
Table 10 -1 Guidance for capturing the study treatment errors including 
misuse/abuse  
Treatment error type  Document in Dosing 
CRF (Yes/No)  Document in AE 
eCRF  Complete SAE form  
Unintentional study 
treatment error  Yes Only if associated with 
an AE  Only if associated with 
an SAE  
Misuse/Abuse  Yes Yes Yes, even if not 
associated with a SAE  
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections.  
10.2 Additional Safety Monitoring 
Not applicable 
10.3 Steering Committee 
A steering committee will be established including disease area experts and investi gators 
participating in the trial.  
The steering committee will ensure transparent management of the study according to the protocol by [CONTACT_37289]. The steering committee will review protocol amendments  as appropriate. Together with the clinical trial 
team, the steering committee will also develop recommendations for publication of study results. The details of the role of the steering committee will be defined in the Steering Committee Charter.  
[COMPANY_001]  Confidential  Page 77  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 11 Data Col lection and Database management  
11.1 Data collection 
Designated investigator staff will enter the data required by [CONTACT_332029] s (eCRF). The eCRFs have been built using fully validated secure web- enabled software 
that conforms to [ADDRESS_410637] been trained. Automatic validation programs check for data discrepancies in the eCRFs, allow modification and/or verification of the entered data by [CONTACT_6649].  
The investigator/designee is responsible for assuring that the data (recorded on CRFs) (entered into eCRF) is complete, accurate, and that entry and updates are performed in a timely manner. The Investigator must certify that the data  entered are complete and accurate 
After final database lock, the investigator will receive copi[INVESTIGATOR_109002].  
All data should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation, and verification. 
11.2 Database management and quality control 
[COMPANY_001] personnel (or designated CRO) will review the data entered by [CONTACT_5375]. Electronic data queries stating the nature of t he problem and 
requesting clarification will be created for discrepancies and missing values and sent to the investigational site via the EDC system. Designated investigator site staff are required to respond promptly to queries and to make any necessary c hanges to the data.  
Concomitant treatments and prior medications entered into the database will be coded using the World Health Organization (WHO) Drug Reference List, which employs the Anatomical Therapeutic Chemical classification system. Medical history /current medical conditions and 
adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. 
Laboratory samples will be processed centrally and the results will be sent electronically to 
[COMPANY_001] (or a designate d CRO).  
Subjects will fill in their PRO data in a site based tablet. The system will be supplied by a vendor, who will also manage the database. The database will be sent electronically to [COMPANY_001] personnel (or designated CRO). 
Randomization codes and data about all study treatment(s) dispensed to the subject and all 
dosage changes will be tracked using an Interactive Response Technology (IRT). The system will be supplied by [CONTACT_5343], who will also manage the database. The data will be sent electronically to [COMPANY_001] at specific timelines.  
Each occurrence of a code break via IRT will be reported to the clinical team and monitor. The code break functionality will remain available until study shut down or upon request of [COMPANY_001]. 
[COMPANY_001]  Confidential  Page 78  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 Once all the necessary actions have been completed and the database has been declared to be 
complete and accurate, it will be locked and the treatment codes will be unblinded and made 
available for data analysis . Any changes to the database after that time can only be made after 
written agreement by [CONTACT_188660]. 
11.3 Site monitoring 
Before study initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] representative will review the protocol and data capture requirements (i.e. eSource DDE or eCRFs) with the investigators and their staff. During the study, [COMPANY_001]  employs several 
methods of ensuring protocol and GCP compliance and the quality/integrity of the sites’ data. The field monitor will visit the site to check the completeness of subject records, the accuracy of data capture / data entry, the adherence to the protocol and to Good Clinical Practice, the progress of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Key study personnel must be available to assist the field monitor during these visits. Continuous remote monitoring of each site’s data may be performed by a centralized [COMPANY_001]  CRA organization. Additionally, a central analytics 
organization may analyze data & identify risks & trends for site operational parameters, and provide reports to [COMPANY_001] clinical teams to assist with trial oversight.  
The investigator must maintain source documents for each subject in the study, consisting of case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical information, laboratory data, electrocardiograms, and the results of any other tests or assessments. All information on CRFs must be traceable to these source documents in the subject’s fi le. The investigator must also keep the original informed consent form signed by [CONTACT_1560] (a signed copy is given to the subject). 
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency with the data capture and/or data entry. [COMPANY_001]  monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all primary variables. Additional checks of the consistency of the source data with the CRFs are performed according to the study- specific monitoring plan. No information in source documents about the identity of the 
subjects will be disclosed.  
12 Data analysis and statistical methods 
Any data analysis carried out independently by [CONTACT_85689]. 
12.1 Analysis sets  
The Randomized Analysis Set (RAS) consists of all randomized subjects. Subjects will be analyzed according to the treatment assigned at randomization. 
The Full Analysis Set (FAS) comprises all subjects to whom study treatment has been assigned. Subjects will be analyzed according to the treatment assigned to at randomization. Mis -
randomized subjects ( mis-randomized in IRT) will be excluded from FAS. Mis -randomized 
subjects are defined as cases where IRT contacts were made by [CONTACT_332030] 79  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 inappropriately prior to confirmation of the subject’s final randomization eligibility and no 
study medication was administered to the subject.  
The Safety Set includes all subjects who received at least one dose of study treatment. Subjects will be analyzed according to the study treatment received, where treatment received is defined as the randomized /assigned treatment if the subject took at least one dose of that treatment or 
the first treatment received if the randomized/assigned treatment was never received.  
12.[ADDRESS_410638]. 
12.4 Analysis of the primary endpoint(s) 
The primary aim of the study is to demonstrate the efficacy of secukinumab (300 mg Q4W) with respect to IGA responder status after 16 weeks of treatment compared to placebo.  The detailed definition and the justification of the corresponding primary estimand will be provided in the Estimand Charter.  
12.4.1  Definition of primary endpoi nt(s) 
The primary endpoint of the study is the proportion of IGA responder at Week 16, where IGA response is defined as achievement of absolute IGA score ≤ 2. 
The analysis of the primary endpoint will be based on the FAS. 
12.4.2  Statistical model, hypothesis, and method of analysis  
The primary endpoint of IGA response at Week 16 is a binary (yes/no) outcome. Bayesian 
inference based on the non -informative prior of Beta (1/3, 1/3) for each treatment group will be 
used to obtain the posterior distrubution of the treatment difference between secukinumab and placebo for the three subtypes, respectively.  
The Bayes PoC criteria to be assessed for the primary endpoint are:  
1) the probability of the treatment difference greater than zero (δ>0) is greater than 90%;  Pr (δ (secukinumab, placebo),wk16 > 0 | data) > 90%   
And 
2) the probability of the treatment difference exceeding half of the target effect of 0.15 (δ>0.15) 
is greater than 50%  
Pr (δ (secukinumab, placebo),wk16 > 0.15 | data) > 50%  
[COMPANY_001]  Confidential  Page 80  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 where δ denotes  the treatment difference between secukinumab and placebo with respect to the 
IGA response at Week 16  
Posterior estimates of the treatment difference and 95% credible interval will be presented. The 
posterior probabilities of achieving the efficacy criteria will be provided. 
12.4.3  Handling of missing values/censoring/discontinuations  
Subjects who discontinue treatment before Week 16  will be considered to be failures.  
12.4.4  Sensitivity and Supportive analyses  
 
            
 
 
 
      
 
   
 
   
 
   
 
12.5 Analysis of secondary endpoints 
12.5.1  Efficacy and /or Pharmacodynamic endpoint(s)  
The secondary endpoints of this study are planned as follow: 
Investigator’s Global Assessment (IGA) score  
IGA responder rate at time points in treatment period [ADDRESS_410639] (if suitable) or the chi -square test will be applied to the IGA responder rate at time points 

[COMPANY_001]  Confidential  Page 81  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 other than week 16 and estimates of the difference of the IGA responder rate between the 300 
mg Q4W treatment regimen and placebo groups together with 95% confidence intervals will be presented.  
Proportion (%) of IGA responders will be presented by [CONTACT_332031]. 
Proportion (%) of subjects achieving 2 points improvement in IGA score will be presented by 
[CONTACT_332032] b aseline up to the end of study for each treatment group. 
Proportion (%) of IGA 0 or 1 will be presented by [CONTACT_332031].  
Dermatology Life Quality Index  
Seven scores will be derived from the DLQI: the total score of each of the six dimensions as 
well as the total score over all items. The higher the score, the more quality of life is impaired. The DLQI total score will be calculated by [CONTACT_37303] a maximum of 30 and a minimum of 0. 
• DLQI responder: DLQI total score 0 or 1 will be considered as responder. Proportion (%) 
of DLQI responder will be presented by [CONTACT_332033]. 
• Summary statistics will be provided for absolute and percentage change from baseline of the total score of each of the six dimensions as well as the total  score by [CONTACT_332034]. 
Physician Assessment of Surface Area of Disease (PSAD) for Skin Disease 
The number and percentage of subjects in each category will be presented by [CONTACT_332034]. 
Patient Assessment of Itch (NRS)  
Summary statistics will be provided for absolute and percentage change from baseline of itching 
NRS score by [CONTACT_332035]. 
Patient Assessment of Pain (NRS) 
Summary statistics will be provided for absolute and percentage change from baseline of pain 
NRS score by [CONTACT_332036]. 
Reticular erythematous Ulcerative (REU) score  
Summary statistics will be provided for absolute and percentage change from baseline of REU 
score by [CONTACT_332037]. 
LPP Activity Index (LPPAI)  
Subjects with an LPPAI reduction greater than 85% over pretreatment values were considered 
responders, with 25% to 85% reduction were considered partial responders, and with less than 
25% reduction were considered non-responders. 
• LPPAI responder and partial responder: LPPAI responder and partial responder will be 
presented by [CONTACT_332033]. 
[COMPANY_001]  Confidential  Page 82  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 • Summary statistics will be provided for absolute and percentage change from baseline of 
LPPAI score by [CONTACT_332033]. 
Oral Lichen Pl anus Symptom Severity Measure (OLPSSM):  
Summary statistics will be provided for absolute and percentage change from baseline of OLPSSM score by [CONTACT_332036]. 
Scalpdex:  
Summary statistics will be provided for absolute and percentage change from baseline 
of Scalpdex score by [CONTACT_332038]. 
12.5.2  Safety endpoints  
All safety evaluations will be performed on the Safety set.  
Adverse events  
Treatment emergent AEs (events started after the first dos e of study treatment and within [ADDRESS_410640] dose of study treatment but increased in severity based on preferred term within 84 days after week 32) will be summarized. Only primary paths within MedDRA will be  considered for AE reporting. 
AEs will be summarized by [CONTACT_1601], for each treatment group, the number and percentage of subjects having any AE, having an AE in each primary system organ class and having each individual AE (preferred term). Summaries will also be presented for AEs by [CONTACT_201092]. If a subject reported more than one AE with the same preferred term, the AE with the greatest severity will be presented. If a subject reported more than one AE within the same pr imary system organ class, the subject will be counted only once with the 
greatest severity at the system organ class level, where applicable.  
Separate summaries will be provided for death, SAE, other significant AEs leading to discontinuation and AEs leading to study treatment discontinuation. 
Vital signs  
Analysis of the vital sign measurements using summary statistics for the change from baseline 
for each post -baseline visit will be performed. These descriptive summaries will be presented 
by [CONTACT_37297]. Change from baseline will only be summarized for subjects with both baseline and post- baseline values.  
Clinical laboratory evaluations  
The summary of laboratory evaluations will be presented for two groups of laboratory tests (hematolo gy and serum chemistry). Descriptive summary statistics for the change from baseline 
to each study visit will be presented. These descriptive summaries will be presented by [CONTACT_109057], laboratory test and treatment group. Change from baseline will only be summarized for subjects with both baseline and post baseline values. 
[COMPANY_001]  Confidential  Page 83  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
   
 
 
 
 
1
2.5.6  PD relationships  
The  other clinically important 
endpoints, such as PSAD, REU, LPPAI will be investigated if appropriate. 
12.5.7  Patient reported outcomes  
Please refer to Section  12.5 or Section  12.6 for the analysis method of Patient reported 
outcomes. 

[COMPANY_001]  Confidential  Page 84  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 12.[ADDRESS_410641] study visit.  
12.8 Sample size calculation  
Total sample size for this study is 108 with 36 subjects in each subtype  
Primary endpoint(s)  
For each su btype, 24 secukinumab 300 mg Q4w treatment regimen subjects and 12 placebo 
subjects assures the  71% probability to claim positive PoC results, based on the assumptions 
that the placebo IGA responder rate is 20% and secukinumab 300 mg Q4w placebo difference  
(delta) of the IGA responder rates is at least 30%.  
For different response rate assumptions on secukinumab 300 mg Q4w and placebo dose 
regimens,  the below figure and table show that there is not much difference on the probability 
to claim a successful PoC  results between randomization ratios 1:1 and 2:1. Considering the 
absence of previous lichen planus secukinumab data, randomization 2:1 is chosen for this study to assure more efficacy and safety data on lichen planus secukinumab subjects. The below figure and table also shows the probability to claim a positive PoC results is around 70% when the secukinumab 300 mg Q4w placebo difference (delta) of the IGA responder rates is 30% in any scenario and greater than 85% when the secukinumab 300 mg Q4w placebo difference (delta) of the IGA responder rates is 40% in any scenario. 

[COMPANY_001]  Confidential  Page 85  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 Figure 12 -1 Operating Characteristics on different randomization ratio and 
different response rate assumption  
  
Table 12 -1 Operating Characteristics on different randomization ratio and 
different response rate assumption  
Secukinumab 
response rate  Placebo response rate Probability to meet target efficacy with 
AIN 18: PBO 18  Probability to meet target efficacy with 
AIN 24: PBO 12   
A(small)=0.4  0.1 0.838  0.793  
B(moderate)=0.5  0.1 0.945  0.923  
C(high)=0.6  0.1 0.987  0.978  
D(very high)=0.7  0.1 0.998  0.996  
E(extreme high)=0.8  0.1 1.000  1.000  
A(small)=0.4  0.2 0.543  0.503  
B(moderate)=0.5  0.2 0.767  0.712  
C(high)=0.6  0.2 0.915  0.871  
D(very high)=0.7  0.2 0.980  0.960  
E(extreme high)=0.8  0.2 0.998  0.993  
A(small)=0.4  0.3 0.282  0.255  
B(moderate)=0.5  0.3 0.520  0.454  
C(high)=0.6  0.3 0.751  0.675  
D(very high)=0.7  0.3 0.908  0.856  
E(extreme high)=0.8  0.3 0.980  0.961  
Operating Characteristics results are from QTD version 3.0.0  

[COMPANY_001]  Confidential  Page 86  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 13 Ethical considerations and administrative procedures  
13.1 Regulatory and ethical compliance 
This clinical study was designed and shall be implemented, executed and reported in accordance 
with the International Conference on Harmoni zation (ICH) Harmonized Tripartite Guidelines 
for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical principles laid down in the Declaration of Helsinki.  
13.2 Responsibilities of the investigator and IRB/IEC 
Before initiating a trial, the investigator/institutio n must obtain approval/favorable opi[INVESTIGATOR_18548]/Independent Ethics Committee (IRB/IEC) for the trial protocol, written informed consent form, consent form updates, subject recruitment procedures (e.g. advertisements) and any other written information to be provided to subjects. Prior to study start, the investigator is required to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol and to give access to all relevant data and records to [COMPANY_001] 
monitors, auditors, [COMPANY_001] Quality Assurance representatives, designated agents of [COMPANY_001], IRBs/IECs, and regulatory authorities as required. If an inspecti on of the clinical site is 
requested by a regulatory authority, the investigator must inform [COMPANY_001] immediately that this request has been made.  
13.[ADDRESS_410642]. In addition, after study completion (defined as last patient last visit) and finalization of the study report the results of this trial will be submitted for publication and posted in a publicly accessi ble database of clinical trial results, such as the [COMPANY_001] clinical trial 
results website and all required Health Authority websites (e.g. Clinicaltrials.gov , EudraCT 
etc) .  
For details on the [COMPANY_001] publication policy including authorship criteria, pl ease refer to the 
[COMPANY_001] publication policy training materials that were provided to you at the trial investigator meetings.  
13.[ADDRESS_410643] Quality Management System (QMS) that includes all activities involved in quality assurance and quality control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and ICH Guidelines.  
Audits of investigator sites, vendors, and [COMPANY_001] systems are performed by [CONTACT_6663], independent from those involved in conducting, monitoring or performing quality control of the clinical trial. The clinical audit process uses a knowledge/risk based approach. 
Audits are conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal SOPs, and are performed according to written [COMPANY_001] processes 
[COMPANY_001]  Confidential  Page 87  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 13.[ADDRESS_410644] be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_6669]/IEC and Health Authorities, where required, it cannot be implemented.  
13.[ADDRESS_410645] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to implementation.  
Only amendments that are required for subject safety may be implemented immediately provided the health authorities are subsequently notified by [CONTACT_6670]/IEC is notified. 
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety of any subject included in this 
study, even if this action represents a deviation from the protocol. In such cases, [COMPANY_001] should be notified of this action and the IRB/IEC at the study site should be informed according to local regulations. 
[COMPANY_001]  Confidential  Page 88  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 [ADDRESS_410646]  
Balci DD, Inandi T (2008) Dermatology life quality index scores in Lichen Planus: 
Comparison of psoriasis and healthy controls. Turkderm; 42:127-30. 
Bruin G, Loesche C, Nyirady J, et al (2017) Population Pharmacokinetic Modeling of 
Secukinumab in Patients With Moderate to Severe Psoriasis. J Clin Pharmacol; 57(7):876-85. 
Burke LB, Brennan MT, Ni Riordain R, et al (2019) Novel Oral Lichen Planus Symptom 
Severity  Measure for assessing patients' daily symptom experience. Oral Dis; 25(6):1564-72. 
Cassol -Spanemberg J, Blanco-Carrion A, Rodriguez-de Rivera-Campi[INVESTIGATOR_331980], et al (2019) 
Cutaneous, genital and oral lichen planus: A descriptive study of [ADDRESS_410647] Bucal; 24(1):e1 -7. 
Chao TJ (2009) Adalimumab in the management of cutaneous and oral lichen planus. Cutis; 
84:325-28. 
Chen SC (2002) Scalpdex: A quality-of- life instrument for scalp dermatitis. Arch Dermatol; 
138:803-07. Cheng H, Oakley A, Conaglen JV, et al (2017) Quality of Life and Sexual Distress in Women 
With Erosive Vulvovaginal Lichen Planus. J Low Genit Tract Dis; 21(2):145–49. 
Chiang C, Sah D, Cho BK, et al (2010) Hydroxychloroquine and lichen planopi[INVESTIGATOR_22785]: efficacy 
and introduction of Lichen Planopi[INVESTIGATOR_331981]. J Am Acad Dermatol; 
62:387-92. 
Chobanian AV, Bakris GL, Black HR, et al (2003) Seventh report of the joint national 
committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension; 42:1206–52. 
Deen K, McMeniman E (2015) Mycophenolate mofetil in erosive genital lichen planus: A 
case and review of the literature. J Dermatol; 42: 311-14. 
Doherty SD, Van Voorhees A, Lebwohl MG, et al (2008) National Psoriasis Foundation 
consensus statement on screening for latent tuberculosis infection in patients with psoriasis 
treated with systemic and biologic agents. J Am Acad Dermatol; 59:209-17. 
Finlay AY, Khan GK. 1994. Dermatology Life Quality Index (DLQI)- a simple practical 
measure for routine clinical use. Clin. Exp. Dermatol; 19(3):210-16. Fonda- Pascual P, Fernández- González P, Moreno -Arrones OM, et al (2018) Pustular 
Secondary Cutaneous Aspergillosis in an Immunosuppressed Patient. Actas Dermosifiliogr; 
109:287-90. 
Gobbo M, Rupel K, Zoi V, et al (2017) Scoring systems for Oral Lichen Planus used by 
[CONTACT_332039]. Med Oral Patol Oral Cir Bucal; 22(5):e562 -71. 
Gorouhi F, Davari P, Fazel N (2014) Cutaneous and mucosal lichen planus: A comprehensive 
review of clinical subtypes, risk factors, diagnosis, and prognosis. Scientific World Journal; 
2014(742826):1-22. 
[COMPANY_001]  Confidential  Page 89  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 Gueiros LA, Arao T, Souza T, et al (2018) IL17A polymorphism and elevated IL17A serum 
levels are associated with oral lichen planus. Oral Dis; 24:377–83. 
Hazra SC, Choudhury AM, Khondker L, et al (2013) Comparative efficacy of methotrexate 
and mini pulse betamethasone in the treatment of lichen planus. Mymensingh Med J; 22(4):787-97. 
Husein -ElAhmed H, Gieler U, Steinhoff M (2019) Lichen planus: a comprehensive evidence-
based analysis of medical treatment. J Eur Acad Dermatol Venereol; 33:1847–62. 
 
Langley RG, Elewski BE, Lebwohl M, et al (2014) Secukinumab in plaque psoriasis- Results 
of two phase 3 trials. N. Engl. J. Med; 371(4):326-38. 
Le Cleach L, Chosidow O (2012) Clinical practice. Lichen planus. N. Engl. J. Med; 
366(8):723-32. 
Lunge S, Patil S, Manjunathswamy BS (2016) A comparative study of methotrexate & low 
molecular weight heparin for the treatment of generalized lichen planus. Ind J Clin and Exp Dermatol; 2(4):153-58. 
Mancia G (2007) Blood pressure reduction and cardiovascular outcomes: Past, present, and 
future. Am. J. Cardiol; 100suppl:3J–9J. 
Manuel O, Kumar D (2008) QuantiFERON-TB® Gold assay for the diagnosis of latent 
tuberculosis infection. Expert Rev. Mol. Diagn; 8(3):247-55. 
Naeini FF, Saber M, Asilian A, et al (2017) Clinical Efficacy and Safety of Methotrexate 
versus Hydroxychloroquine in Preventing Lichen Planopi[INVESTIGATOR_331982]: A Randomized 
Clinical Trial. Int J Prev Med; 8:37 -44. 
Neuenschwander B, Wandel S, Roychoudhury S, et al (2015) Robust exchangeability designs for early phase clinical trials with multiple strata. Pharmaceut Statist; 15:123 -34. 
Park HK, Hurwitz S, Woo SB (2012) Oral lichen planus: REU scoring system correlates with pain. Oral Surg Oral Med Oral Pathol Oral Radiol; 114(1):75-82. 
Patrick DL, Burke LB, Powers JH, et al (2007) Patient-reported outcomes to support medical 
product labeling claims: FDA perspective. International Society for Pharmacoeconomics and 
Outcomes Research; 10(2):S125–S137. 
Pi[INVESTIGATOR_331983], Treister N, Pi[INVESTIGATOR_331984] W, et al (2005) Scoring system for monitoring oral 
lichenoid lesions: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 99(6):696-703. 
Radwan -Oczko M, Zwyrtek E, Owczarek JE, et al (2018) Psychopathological profile and 
quality of life of patients with oral lichen planus. J Appl Oral Sci; 26:1-9. Schmidt T, Solimani F, Pollmann R, et al (2018) TH1/TH17 cell recognition of desmoglein 3 
and bullous pemphigoid antigen 180 in patients with lichen planus. J. Allergy Clin. Immunol; 
142(2):669-72. 

[COMPANY_001]  Confidential  Page 90  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 Shaker O, Hassan AS (2012) Possible role of interleukin-17 in the pathogenesis of lichen 
planus. Br. J. Dermatol; 166:1367-68. 
Solimani F, Pollmann R, Schmidt T, et al (2019) Therapeutic Targeting of Th17/Tc17 Cells 
Leads to Clinical Improvement of Lichen Planus. Front Immunol; 10:1-10. 
Thandar Y, Maharajh R, Haffejee F, et al (2019) Treatment of cutaneous lichen planus (Part 
1): A review of topi[INVESTIGATOR_22729]. Cogent Medicine; 6:1-21. 
Thongprasom K, Dhanuthai K (2008) Steriods in the treatment of lichen planus: a review. J 
Oral Sci; 50(4):377-85. 
Tziotzios C, Brier T, Lee JYW, et al (2018) Lichen planus and lichenoid dermatoses: 
Conventional and emerging therapeutic strategies. J. Am. Acad. Dermatol; 79:807-18. 
Welz-Kubiak K, Reich A, Szepi[INVESTIGATOR_22938] (2017) Clinical Aspects of Itch in Lichen Planus. 
Acta Derm. Venereol; 97:505–08. 
Yang CC, Khanna T, Sallee B, et al (2018) Tofacitinib for the treatment of lichen planopi[INVESTIGATOR_22785]: 
A case series. Dermatol Ther; 31:1 -4. 
Zakrzewska JM, Chan ES, Thornhill MH (2005) A systematic review of placebo-controlled randomized clinical trials of treatments used in oral lichen planus. Br. J. Dermatol; 
153(2):336-41. 
Zhang J, Zhou G, Du GF, et al (2011) Biologics, an alternative therapeutic approach for oral 
lichen planus. J. Oral Pathol. Med; 40:521–24. 
[COMPANY_001]  Confidential  Page 91  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 15 Appendices  
15.1 Appendix 1: Clinically notable laboratory values and vital signs 
Clinically notable laboratory values  
The following criteria will be used to define expanded limits and notable abnormalities of key 
laboratory tests. 
No specific action is pre -defined within this protocol to respond to specific abnormal laboratory 
values, as it will be decided by [CONTACT_332040], taking into account the overall status of the subject. 
Liver F unction and Related Variables  
Alanine transaminase (ALT) (SGPT): > 3 x Upper Limit of Normal (ULN)  
Aspartate transaminase (AST) (SGOT): > [ADDRESS_410648]  
Total bilirubin: > [ADDRESS_410649] Alkaline phosphatase: > 2.[ADDRESS_410650] Renal Function  
Creatinine (serum): > 1.[ADDRESS_410651] Hematology 
Hemoglobin: ≥ 2 g/dl decrease from baseline  
Platelet count: < Lower Limit of Normal (LLN)  
White blood cell count: < 0.[ADDRESS_410652] Neutrophils: < 0.[ADDRESS_410653] Eosinophils: > 1.[ADDRESS_410654] Lymphocytes: > 1.[ADDRESS_410655].   
[COMPANY_001]  Confidential  Page 92  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
  

[COMPANY_001]  Confidential  Page 93  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 15.3 Appendix 2: Determination of Tuberculosis status 
Determination of tuberculosis (TB) status will be required before administration of study 
treatment and should be performed as defined by [CONTACT_13144]. TB status must be determined by [CONTACT_9870], signs, symptoms and TB central lab testing. Any significant findings will be recorded in the relevant TB assessment eCRF and the Medical History eCRF, as necessary.  
A central lab testing will be performed to assess the TB status at screening for all subjects. This test will only be used to determine subject’s eligibility for the trial. The test will be used to screen the subject population for latent tuberculosis infection ( Doherty et  al 2008).  
This blood- based assay is specific for Mycobacterium tuberculosis and is not influenced by 
[CONTACT_37257] -Guérin vaccination or by [CONTACT_332041]. 
Furthermore, this test, in contrast to the purified protein derivative ([COMPANY_003]) skin test, is also insensitive to a booster effect since the subject is not exposed to the vaccine. The a ssay measures 
the production of interferon-gamma and presents it relative to a negative and a positive control sample ( Manuel  and Kumar  2008). The tuberculosis assay test will be supplied by [CONTACT_11378]. Details on the collection, shipment of samples and reporting of results by [CONTACT_37259]- specific laboratory manual.  
Positive or indeterminate tests must be recorded on the Tuberculosis assessment eCRF; the workflow of sample handling in case of positive or indeterminate test results is provided in Figure 15-1. 
a. If the test result is negative , the subject may be randomized. 
b. If the test result is positive , the investigator should perform a work -up for the test result as 
per local procedures. If a TB work -up was conducted prior to the screening of the subject, results 
of the work -up can be used to assess eligibility if the work- up was conducted within 12 weeks 
prior to ran domization. 
Subjects positive  for latent TB per work -up may be randomized to the trial if sufficient 
treatment has been initiated according to local routine clinical practice and will be maintained for the prescribed duration. Subjects positive for active TB per work -up are not eligible for the 
study. Subjects negative for TB (no signs of latent or active TB) per work- up may be 
randomized to the trial.  
c. If the test result is indeterminate , the investigator may repeat the test once or may proceed 
directly to perform the work -up for the test result as per local procedures. This action is at 
the discretion of the investigator. If a TB work- up was conducted prior to the screening of the 
subject, results of the work- up can be used to assess eligibility if the w ork-up was conducted 
within [ADDRESS_410656] will not be eligible for randomization if “active tu berculosis is present ”or“ latent tuberculosis is present” and is untreated per local 
guidelines. 
[COMPANY_001]  Confidential  Page 94  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 iii. Subjects negative for TB per workup (no signs of latent or active TB) may be randomized 
to the trial if the workup was conducted [ADDRESS_410657] result and a TB work -up (i.e., no second TB test 
will be performed), the TB test to assess eligibility must have been done via the central 
laboratory for the study within the Screening Period (within 4 weeks prior to randomization) and TB work- up will only be considered if it was completed within 12  weeks prior to 
randomization. 
[COMPANY_001]  Confidential  Page 95  
Clinical Trial Protocol Amendment Version 02 ( clean ) Protocol No. CAIN457S12201  
 
 Figure 15 -1 Tuberculosis screening flowchart  
 
